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Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by 
several motor signs including chorea, rigidity, and bradykinesia, as well as cognitive and 
psychiatric symptoms. This disease is caused by a poly-glutamine repeat expansion in the 
N-terminal region of huntingtin (Htt) and mainly affects the striatum despite the 
ubiquitous expression of Htt. Several mechanisms have been suggested for the striatal 
specificity of HD ranging from changes in striatal-enriched proteins like Rhes to 
excitotoxicity from corticostriatal projections.  The transcription factor Ctip2, which is 
preferentially expressed in the striatum, hippocampus, and cortical subplate, is also 
impaired in HD.  Given the putative role of Ctip2 in the regulation of inositol 
polyphosphate multikinase (IPMK), we hypothesized that IPMK is involved in the 
pathophysiology of HD. 
 
IPMK is known for its various functions in regulating cell survival and death through 
soluble kinase and PI3-kinase activities, which produce the inositol phosphates IP4 and 
IP5, and the phosphatidylinositol PIP3, respectively. IPMK also displays various non-
catalytic interactions, including the regulation of mTOR signaling and CBP/p300-
mediated transcription. We have detected a significant loss of IPMK in post-mortem HD 
striatal tissues and various cellular and animal models of the disease. The depletion of 
IPMK protein and mRNA result from mutant Htt-induced impairment of Ctip2, as well as 
alterations in IPMK protein stability. Overexpression of IPMK rescues the mitochondrial 
metabolic activity deficit in a cellular model of HD. This rescue requires the lipid kinase 
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activity of IPMK and implicates the Akt signaling pathway downstream of IPMK 
signaling in HD. More importantly, viral delivery of IPMK in the striatum improves 
striatal pathology and motor performance of a transgenic mouse model of HD.  
 
Our findings indicate that IPMK is an important player in the pathophysiology of HD. 
Furthermore, this Ctip2/IPMK/Akt signaling pathway provides a novel therapeutic target 
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Huntington’s disease (HD) is a progressive and fatal neurodegenerative disorder.  It 
shares several common features with other neurodegenerative diseases such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD).  These similar clinical and 
pathological features include delayed onset of symptoms, selective neuronal 
vulnerability, protein aggregation, and impaired cellular processes such as abnormal 
proteasomal degradation and mitochondrial deficits.  The resulting neuronal dysfunction 
and neuronal death contribute to the motor and cognitive deficits as well as psychiatric 
symptoms evident in patients afflicted with these diseases.  Although much progress has 
been made in understanding the molecular mechanisms involved in these diseases, the 
mechanisms resulting in selective neuronal death are unclear and a cure is still lacking for 
these neurodegenerative diseases.   
 
Huntington’s disease is unique among these diseases in that the genetic cause of HD, 
mutant huntingtin (mHtt), is well established.  Given the similarities of HD with PD and 
AD, understanding the mechanisms for impaired cellular functions in HD may shed light 
on the pathophysiology of these other neurodegenerative diseases.  Although much 
progress has been made in understanding HD and the role of mHtt in impairing cellular 
functions, the mechanisms for the selective neuronal dysfunction and death remain to be 
elucidated.  Various cell autonomous mechanisms, as well as mechanisms relying on cell-
cell interactions such as excitotoxicity from corticostriatal projections have been 
suggested.  It is likely that these mechanisms act synergistically and target several key 
2 
 
proteins resulting in the impairment of a vast signaling network.  Although key signaling 
pathways such as the BDNF/TrkB/Akt pathway have been identified, it is unclear how 
these pathways link together. 
 
The inositol polyphosphate pathway is a complex, evolutionarily-conserved pathway that 
is required for numerous cellular functions ranging from endocytosis to ion channel 
regulation.  Although most enzymes in this pathway phosphorylate inositol phosphates, 
inositol polyphosphate multikinase (IPMK) is a multi-functional enzyme that displays an 
inositol phosphate kinase activity, a lipid kinase activity, and several non-catalytic 
functions.  Through these various catalytic and non-catalytic functions, IPMK regulates 
both cell survival and death. 
 
Given the pleiotropic functions of IPMK, we sought to determine whether this enzyme 
plays a central role in the pathophysiology of HD and identify which of its multiple 
functions are relevant in this disease.  Furthermore, the regulation of IPMK expression 
and activity remains to be elucidated.  Ultimately, understanding the role of IPMK in this 
disease may clarify the vast signaling network contributing to HD and also provide novel 
































1.1 Cellular functions of IPMK 
 
Inositol polyphosphate multikinase (IPMK) is a multi-functional enzyme belonging to the 
family of inositol phosphate kinases, which share motifs allowing for inositol phosphate 
binding and adenosine triphosphate (ATP) binding (1).  This family also includes the 
InsP6 kinases (IP6K) and Ins(1,4,5)P3-kinases (IP3K).  IPMK and other members of the 
inositol phosphate kinase family display a soluble inositol phosphate kinase activity.  
IPMK also demonstrates a lipid kinase activity, as well as several non-catalytic functions.  
 
IPMK was first identified as a crucial enzyme in the inositol polyphosphate pathway 
where it specifically acts as a dual-function inositol trisphosphate (IP3) and inositol 
tetrakisphosphate (IP4) kinase (2-5).  Overall, the inositol polyphosphate pathway 
consists of almost 60 inositol phosphate isomers (1). Collectively, these isomers are 
involved in a variety of cellular functions ranging from channel regulation to chromatin 
remodeling (6).  The lipid kinase activity of IPMK, producing phosphatidylinositol 
(3,4,5)-triphosphate [PtdIns(3,4,5)P3 or PIP3], was subsequently identified.  Through PIP3 
signaling, IPMK is a major regulator of Akt activation (7, 8).  More recently, various 
kinase-independent functions of IPMK were elucidated, including its roles in mammalian 
target of rapamycin (mTOR) signaling, 5’ AMP-activated protein kinase (AMPK) 
regulation, p53-mediated cell death, and cAMP response element-binding protein 
(CREB)-mediated immediate early gene (IEG) induction (9-12).  The various functions 
of IPMK are described in more detail in this chapter 
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1.1.1 Inositol phosphate kinase activity 
 
The inositol phosphate backbone, myo-inositol, consists of a cyclohexanol with a 2-
hydroxyl group in the axial position while the remaining five hydroxyl groups are 
equatorial (1).  Phosphorylation of different hydroxyl groups generates different members 
of the inositol polyphosphate pathway, which is involved in various cellular functions.  
 
Inositol polyphosphate pathway 
Ins(1,4,5)P3 or IP3 is involved in a myriad of cellular functions, the most extensively 
studied function being intracellular calcium (Ca2+) signaling (13).  IP3 also gives rise to 
additional inositol phosphates, including the inositol tetrakisphosphates Ins(1,3,4,5)P4 
and Ins(1,4,5,6)P4 (both known as IP4), the inositol pentakisphosphate Ins(1,3,4,5,6)P5 
(IP5), the inositol hexakisphosphate Ins(1,2,3,4,5,6)P6 (IP6), and the higher inositol 
polyphosphates, which are discussed later  (6) (Figure 1.1).  IP3 is generated by the 
activation of phospholipase C (PLC) in response to ligand-receptor interactions.  PLC 
hydrolyzes the lipid phosphatidylinositol-4,5-bisphosphate [PtdIns(4,5)P2 or PIP2] to 
produce IP3 and the lipid-soluble diacylglycerol (DAG).  IP3 is phosphorylated by IPMK 
or IP3K to generate IP4, which is subsequently phosphorylated by IPMK to produce IP5.  
Thus, IPMK is an inositol trisphosphate and tetrakisphosphate 6/5/3-kinase. Although 
there is some redundancy in the inositol polyphosphate pathway, IPMK is the only 
enzyme that can produce Ins(1,4,5,6,)P4 and IP5 (14). Interestingly, IP3K null mouse 
embryonic fibroblasts (MEFs) still produce IP5 and IP6, indicating that IPMK is crucial in 







Figure 1.1.  Soluble inositol polyphosphate kinase activity of IPMK 
IPMK phosphorylates IP3 to produce Ins(1,4,5,6)P4 and Ins(1,3,4,5)P4 both known as IP4.  Ins(1,3,4,5)P4 also results from the catalytic 
activity of IP3K.  IPMK phosphorylates IP4 to produce Ins(1,3,4,5,6)P5, which is subsequently phosphorylated by inositol 1,3,4,5,6-
pentakisphosphate 2-kinase (IPPK or IPK1) to produce Ins(1,2,3,4,5,6)P6.  The higher inositol phosphates, containing pyrophosphate 
moieties, are not shown.  Circles indicate phosphate groups. 
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IPMK in yeast  
IPMK was first identified as the Saccharomyces cerevisiae homolog, Arg82.  Within 
yeast, the inositol phosphate kinase activity of Arg82 is required for numerous cellular 
functions including the yeast transcriptional response to arginine (16), nucleosome 
mobilization and chromatin remodeling (17, 18), and the cellular response to nitrogen 
source quality and phosphate availability (19).   
 
The ArgR-Mcm1 complex, consisting of Arg80, Arg81, Arg82, and minichromosome 
maintenance protein 1 (Mcm1), is an arginine-responsive transcription complex.  Arg82 
is required for the formation of this complex independent of its soluble inositol phosphate 
kinase activity.  However, IP4 and possibly IP5 are essential for the ArgR-Mcm1 
complex-mediated transcriptional regulation of target genes as demonstrated by growth 
on ornithine as the only source of nitrogen (16).  Interestingly, other studies focusing 
specifically on genes that regulate arginine metabolism indicate a role for a non-catalytic 
activity of Arg82 (20).  Specifically, Arg82 represses ornithine carbamoyltransferase 
(OTCase) induction and enhances arginase induction by arginine independently of IP4 
and IP5 production.  The non-catalytic functions of Arg82 are described in section 1.1.3. 
 
Arg82 is also involved in chromatin remodeling in yeast.  IP4 and IP5 regulate the 
SWI/SNF (SWItch/Sucrose Non-Fermentable) complex, a nucleosome-remodeling 
complex that enhances transcription in an ATP-dependent manner (17).  In addition to 
regulation of the SWI/SNF complex, the inositol polyphosphates regulate Ino80, another 
ATP-dependent chromatin-remodeling complex (18).  Recruitment of these chromatin-
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remodeling complexes to phosphate-responsive promoters and the subsequent induction 
of genes such as PHO5 relies on IP4 and possibly IP5.  Although the exact mechanism is 
unknown, the inositol phosphates may act by regulating the interaction between the 
SWI/SNF or Ino80 complexes with chromatin.  Furthermore, IP4 and IP5 may contribute 
to the combinatorial signaling pathways regulating the activation of specific complexes. 
 
The soluble inositol phosphate kinase activity of Arg82 was also demonstrated to be 
required for the induction of nitrogen-regulated genes and the repression of phosphate-
regulated genes (19).  Although the mechanism and the specific inositol polyphosphate 
products of Arg82 required for nitrogen and phosphate sensing are not known, the 
inositol polyphosphates may be acting through the regulation of chromatin-remodeling 
complexes.  
 
Several other Arg82-dependent processes in yeast have been described including 
activation of macroautophagy, a complex lysosome-dependent process of degradation 
(21) and mRNA export (22).  However, the mechanisms for these processes are 
unknown.  In nitrogen-deprived conditions, yeast requires both Arg82 and KCS1 (the 
yeast homolog of IP6K1) for vacuolar processing, an essential step in autophagy (21).  As 
described earlier, Arg82 produces IP4 and IP5, while KCS1 phosphorylates IP6 to 
generate the higher inositol polyphosphate 5-PP-Ins(1,2,3,4,6)P5 or 5-IP7.  The 
involvement of several enzymes of the inositol polyphosphate pathway in autophagy 
suggests that this cellular process may be dependent on the production of inositol 





Table 1.1.  Physiologic roles of IP4 and IP5 in yeast  
 
Process IPx References 
Chromatin remodeling IP4 (and IP5) (17, 18) 
Regulation of gene expression IP4 and IP5 (16) 
Phosphate and nitrogen sensing Unknown (19) 
Autophagy Unknown (21) 

















IPMK in mammalian cells 
In mammalian cells, IP4 and IP5 regulate several enzymes, signaling pathways, and 
cellular processes.  Numerous crucial signaling proteins contain a pleckstrin homology 
(PH) domain, a 120-amino acid stretch comprised of seven β strands and a C-terminal α 
helix.  These PH domains influence cellular localization by binding to inositol phosphates 
and phosphatidyl inositols (23). Interestingly, different pleckstrin homology domains 
display specificity for distinct inositol phosphates and phosphoinositides, such as PIP2 
and PIP3.  Pyruvate dehydrogenase kinase, isozyme 1 (PDK1) contains a PH domain that 
binds to PIP3 and PIP2 thereby allowing for membrane targeting and subsequent 
activation of the Akt/protein kinase B (PKB) signaling pathway described in section 
1.1.2.  This PH domain can also bind IP5 and IP6, allowing for cytoplasmic retention of 
PDK1 and activation of non-membrane targets (24).  IP5 also binds the PH domain of 
Akt, inhibiting membrane translocation and the subsequent phosphoinositide 3-kinase 
(PI3K)/Akt signaling pathway (24-26).  Thus, IP5 affects numerous cellular pathways 
requiring Akt activation.  For instance, in endothelial cells, IP5 inhibits basic fibroblast 
growth factor (FGF-2)-induced survival, cell migration, and angiogenesis as 
demonstrated by impaired capillary tube formation (26).  Through the inhibition of Akt, 
IP5 also exerts a pro-apoptotic effect in various cancer lines, including ovarian, breast, 
and lung cancer cells (27).  Thus, one of the unique catalytic products of IPMK, IP5, 
might act as a molecular switch regulating the activation of Akt.  
 
Similarly, Bruton’s tyrosine kinase (BTK), a cytoplasmic tyrosine kinase involved in B 
lymphocyte activation and development, contains a PH domain that binds Ins(1,3,4,5)P4, 
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IP5, and IP6. X-linked agammaglobulinemia (XLA) and murine X-linked 
immunodeficiency (Xid) contain mutations in the PH domain of BTK resulting in 
decreased IP4 binding and altering hematopoietic cell differentiation (28).  Ins(1,3,4,5)P4 
is also involved in the development of T lymphocytes by binding interleukin-2-inducible 
T cell kinase (ITK).  ITK is subsequently recruited to PIP3 at the cell membrane where 
ITK phosphorylates PLC-γ1 (29). This mechanism is crucial for T cell receptor signaling 
during thymocyte positive selection.  Other PH domain-containing proteins have been 
shown to interact with inositol phosphates, including Gap1m (30), and Gap1IP4BP (31), 
both members of the Ras GTPase-activating protein family.  These studies implicate the 
inositol phosphates in an additional layer of complexity in phosphoinositide signaling 
resulting from the role of the inositol phosphates in modulating the affinity of various PH 
domains to PIP3.  
 
The soluble inositol phosphate kinase activity of IPMK modulates additional signaling 
pathways that do not involve PH domains.  In the canonical Wnt/β-catenin signaling 
pathway, Wnt ligand binds Frizzled (Fz) and its co-receptor low-density lipoprotein 
receptor related protein 6 (LRP6).  Interaction of this complex with the scaffolding 
protein Dishevelled (Dvl) recruits the Axin complex, which is subsequently 
phosphorylated by LRP6.  In the absence of Wnt, the Axin complex, consisting of the 
scaffolding protein Axin, adenomatous polyposis coli protein (APC), casein kinase 1 
(CK1), and glycogen synthase kinase 3β (GSK3β), phosphorylates β-catenin, targeting it 
for ubiquitination and subsequent degradation.  In the presence of Wnt, phosphorylation 
of β-catenin is inhibited, allowing nuclear translocation of β-catenin, where it binds the 
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LEF/TCF (lymphoid enhancing factor/T-cell factor) transcription factors and induces 
Wnt-responsive genes (32).   
 
In addition to the canonical pathway, Wnt3a stimulation results in Dvl3-mediated 
translocation of IPMK to the cell membrane through the interaction of Dvl3 with the N-
terminal region of IPMK (33). The subsequent IP5 generation is required to inhibit 
GSK3β and stimulate casein kinase 2 (CK2) collectively resulting in β-catenin 
stabilization and enhanced LEF/TCF activation (34).  The inositol polyphosphates, 
specifically Ins(1,3,4,5)P4 and IP5 have also been shown to directly activate casein kinase 
2 (35), a ubiquitously expressed serine/threonine kinase involved in numerous cellular 
processes ranging from cell cycle progression and transcription to apoptosis. (36).  
 
The inositol polyphosphates also regulate global transcription through histone 
deacetylase enzymes (HDAC).  HDAC inhibits transcription by removing acetyl groups 
from histone tails resulting in heterochromatin formation.  Ins(1,4,5,6)P4 promotes the 
assembly of HDAC3 to the deacetylase-activation-domain (DAD) of the SMRT/NCoR 
(silencing mediator for retinoid and thyroid receptors/nuclear receptor co-repressors) co-
repression complex (37) .  This interaction enhances HDAC3 activation.  Thus, this 
pathway provides a likely mechanism for the role of IPMK and IP4 in chromatin 
remodeling.  Additional roles for IP4 and IP5 include the regulation of L-type calcium 
channels in vascular smooth muscle cells (38), IP3 metabolism (39), and hemoglobin 
(Hb) affinity for oxygen (O2) (40).  The physiologic roles of the inositol phosphate kinase 





Table 1.2.  Physiologic roles of IP4 and IP5 in mammalian cells 
 
Protein  Effect of IPx IPx References 
Akt  Inhibition of PH domain and Akt signaling IP5 (24-27) 
PDK1  Inhibition of PH domain and cytoplasmic 
retention of PDK1 
IP5 (24) 
BTK  B cell activation and development Ins(1,3,4,5)P4 (28, 29) 
ITK  T cell development (thymocyte positive 
selection) 
 (32) 
GAP1IP4BP  Enhanced Ras GAP activity  Ins(1,3,4,5)P4 (30, 31)  
GAP1m Enhanced Ras GAP activity Ins(1,3,4,5)P4 (34) 
Wnt  GSK3β inhibition and β-catenin-induced 
LEF/TCF activation  
IP5 (33, 34) 
CK2  Enhanced catalytic activity Ins(1,3,4,5)P4, IP5 (35) 
HDAC HDAC-co-repressor assembly and chromatin 
remodeling  
Ins(1,4,5,6)P4 (37) 
Ca2+ channel  L-type Ca2+ channel stimulation in vascular 
smooth muscle cells  
IP5 (38) 
IP3 5-phosphatase Inhibition of IP3 hydrolysis Ins(1,3,4,5)P4 (39) 
Hb-O2 Reduced affinity of Hb for O2 IP5 (40) 
    
    





The production of IP5 is the rate-limiting step for the production of the highly-energetic 
diphosphoinositol phosphates, also known as the higher inositol polyphosphates or 
inositol pyrophosphates.  IP5 is phosphorylated by IP5 2-kinase (IPPK) to produce IP6 
(Figure 1.1), one of the starting products for the generation of the higher inositol 
polyphosphates, which include 5-PP-IP4, 1-IP7, 5-IP7, and 1/5-IP8 (6, 41).  In fact, IPMK 
deletion in MEFs abolished the synthesis of IP5, as well as the higher inositol 
polyphosphate IP7 (42).  These inositol pyrophosphates are involved in various cellular 
functions including the regulation of telomere length (43, 44), insulin secretion (45), 
endocyte trafficking (46), and homologous recombination repair of damaged DNA (47). 
The inositol pyrophosphates also contribute to post-translational modifications through 
the addition of a phosphate group onto phosphorylated residues (48, 49).  Thus, IP5 is 
also indirectly involved in numerous cellular processes through the production of IP6 and 
the higher inositol polyphosphates.  
 
1.1.2 Lipid kinase activity 
 
Phosphatidyl Inositol 3-kinase  
Class I PI3K, which phosphorylates the 3-hydroxyl group of the inositol ring of 
phosphoinositides, is the main player in the canonical lipid kinase signaling pathway 
(50). Class I PI3K consists of a p85-p110 complex.  Receptor activation and 
autophosphorylation of tyrosine residues promotes receptor interaction with p85, which 
subsequently activates p110, the catalytic subunit.  Class I PI3Ks produce PI(3)P, 
PI(3,4)P2, and PI(3,4,5)P3 (51).  Class II PI3Ks are thought to specifically produce PI(3)P 
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while the Class III PI3K is a PtdIns-specific vacuolar protein sorting-associated protein 
34 (VPS34) involved in various cellular processes including autophagy and amino acid 
sensing (50, 52).  
 
Lipid kinase activity of IPMK 
IPMK displays a lipid kinase or PI3-kinase activity similar to Class I PI3Ks (51) (Figure 
1.2).  Interestingly, IPMK is more selective than PI3K since it only produces PIP3 
whereas PI3K produces PI(3)P, PI(3,4)P2, and PI(3,4,5)P3.  Although IPMK is not 
directly inhibited by wortmannin (51), wortmannin prevents IPMK phosphorylation and 
activation (7).  Wortmannin inhibits PI3Ks. Therefore, PI3K-mediated PIP3 production is 
thought to activate specific kinases that subsequently phosphorylate and activate IPMK, 
creating a feed-forward loop amplifying PIP3 production (7).  The proposed kinases and 
phosphorylation sites regulating IPMK remain to be identified.  In vitro competition 
assays using IP3 and Ins(1,3,4,6)P4 in the presence of PIP2 indicate that PIP2 competes 
successfully with the inositol phosphates as IPMK substrates (51).  Phosphorylation of 
IPMK may add another level of regulation enhancing the lipid kinase activity of IPMK.   
 
As described earlier, the PH domain is a loosely conserved stretch of 120 amino acids, 
which recognizes PIP2 and PIP3 and promotes the recruitment of proteins to the cell 
membrane (50). Through the production of PIP3, PI3K leads to the activation of various 
PI3K effectors containing PH domains, including Akt, PDK1, PLCγ, BTK, ITK, and 
GAPs among others (53).  Collectively, these effector molecules influence numerous 







Figure 1.2.  Lipid kinase activity of IPMK   
IPMK and the p110 PI3-kinase (PI3K) both phosphorylate PtdIns(4,5)P2  (or PIP2) to 
produce PtdIns(3,4,5)P3 (or PIP3).  PtdIns(4,5)P2  can also be cleaved by phospholipase C 
(PLC) thereby generating Ins(1,4,5)P3, the starting product of the inositol polyphosphate 





expression and cell growth.  Several effector proteins, including Akt, are discussed next.   
 
Downstream signaling pathways 
Akt/PKB, a serine/threonine kinase, is involved in a myriad of cellular functions such as 
proliferation, survival, growth, and metabolism through the inhibition of various 
substrates.  The substrates include Bcl-2-associated death promoter (BAD), tuberous 
sclerosis 2 (TSC2), forkhead box protein O1 (FOXO1), and p21 among others (50). Akt 
localizes to the membrane through the interaction of its PH domain with PIP3. The 
subsequent phosphorylation of Akt at the T308 and the S473 sites by PDK1 and 
mTORC2 (mTOR complex 2), respectively, results in the activation of the Akt signaling 
pathway (54). The mTORC2 complex consists of mTOR associated with rapamycin-
insensitive companion of mTOR (rictor).  An RNAi-based screen designed to identify 
modulators of Akt activation revealed that IPMK influences the phosphorylation status of 
Akt (8).  This observation was further confirmed in IPMK null MEFs, which display 
decreased phosphorylation of Akt at both the T308 and S473 sites (7).  T308 
phosphorylation reflects IPMK-mediated PIP3 production.  IPMK also acts as a co-factor 
for mTORC2 possibly promoting S473 phosphorylation; however, the mechanism 
remains unknown (10).  Therefore, through its regulation of Akt, IPMK influences 
numerous pathways affecting cell survival, growth, proliferation, and migration (54).  
 
The lipid kinase activity of IPMK also regulates additional proteins. Steroidogenic factor-
1 (SF-1) regulates the transcription of endocrine-associated genes including various 
steroidogenic enzymes and peptide hormones.  SF-1 contains a deep hydrophobic ligand-
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binding domain (LBD) allowing for binding with PIP2 such that the acyl chains are 
buried in the LBD. The inositol polyphosphate head is exposed at the surface of this non-
membrane protein/lipid complex.  IPMK, but not PI3K, interacts with and phosphorylates 
PIP2 to produce SF-1/PIP3, which is required for the transcriptional activity of SF-1 (55).  
 
The lipid kinase activity of IPMK is also involved in mRNA export.  Specifically, IPMK 
is required for ALY mediated mRNA recognition at the 3’ untranslated region (UTR) and 
release from nuclear speckle domains.  Through this mechanism, IPMK selectively 
regulates the export of transcripts involved in genome duplication and repair (56).  
Interestingly, like SF-1, ALY is also known to form a complex with PIP2 or PIP3, which 
regulates the mRNA export activity of this non-membrane protein/lipid complex (57).  
The lipid kinase activities of IPMK are summarized in Table 1.3.   
 
1.1.3 Non-catalytic activities 
 
The non-catalytic roles of IPMK were first identified using the yeast homolog Arg82. 
The regulation of arginine metabolism in yeast requires Arg82, Arg80, Arg81, and 
Mcm1, and results in arginine-induced anabolic gene repression and catabolic gene 
induction (58).  The aspartate stretch of Arg82 is sufficient to stabilize members of the 
MADS-box (Mcm1, agamous, deficiens and serum response factor [SRF]) family of 
transcription factors, Arg80 and Mcm1, by preventing their degradation and promoting 
their nuclear localization (19, 58) (Figure 1.3A).  In fact, the stability of both Arg80 and 






Table 1.3.  Summary of lipid kinase activity of IPMK 
 
 
Protein Cellular processes References 
Akt  Cell survival, growth, proliferation (7, 8) 
SF-1 Endocrine transcriptionl network (55) 


















ortholog of Arg82, which lacks the aspartate stretch (19, 20).  Furthemore, catalytically 
inactive Arg82 does not impair the regulation of arginine metabolism (59).  
 
IPMK is similarly a key regulator of metabolism signaling networks in mammalian cells 
through its regulation of mTOR and AMPK.  mTORC1 (mTOR complex I) exists in a 
complex with raptor (regulatory associated protein by mTOR) and is crucial for nutrient 
amino acid-mediated regulation of protein synthesis and cell growth. Through its N-
terminal domain, IPMK interacts with and stabilizes mTORC1 specifically enhancing 
mTOR-raptor interaction (10) (Figure 1.3B).  AMPK is an energy sensor that promotes 
catabolic pathways while inhibiting anabolic pathways such as fatty acids synthesis and 
mitochondrial biogenesis (60).  Glucose promotes IPMK-AMPK binding in the 
hypothalamus and prevents liver kinase B1 (LKB1)-mediated phosphorylation of AMPK 
at the T172 residue thereby preventing AMPK activation.  This interaction requires the 
tyrosine phosphorylation of IPMK at the Y174 residue (9) (Figure 1.3B).  Through its 
regulation of mTOR and AMPK, IPMK appears to regulate both cellular metabolism as 
well as central metabolism.  
 
More recent studies have also demonstrated a kinase independent role for IPMK as a 
transcriptional co-activator in mammalian cells (Figure 1.3B).  IPMK binds p53 thereby 
enhancing its interaction with p300.  The subsequent acetylation of p53 promotes the 
expression of various downstream targets including Puma, resulting in decreased cell 
viability (12).  In addition to its role in modulating cell death, IPMK influences the 
induction of immediate early genes (IEGs), which play a role in synaptic plasticity and 
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long-term memory (61).  IPMK interacts with CREB-binding protein (CBP), increasing 
its function as a transcriptional co-activator of CREB and leading to IEG induction (11).  
IPMK also binds directly with SRF, enhancing its interaction with serum response 
elements (SRE) and promoting IEG expression among other target genes (62).  As a 
result, conditional deletion of IPMK in neurons cause spatial learning and memory 
deficits in vivo (11).  The non-catalytic activities of IPMK are summarized in Figure 1.3.     
 
Given the pleiotropic roles of IPMK, this enzyme is crucial for the development and 
survival of organisms. In fact, yeast mutants lacking IPMK demonstrate sporulation, 
mating, and stress response deficits (51).  IPMK knockout mice die at embryonic age 9.5 
due to morphological defects including impaired neural tube formation (42).  
Furthermore, neurotrophic factors, which promote neuronal survival and differentiation, 













Figure 1.3.  Non-catalytic activities of Arg82 and IPMK 
(Figure on following page) 
 
(A) The aspartate stretch of Arg82 stabilizes Arg80 and Mcm1, enabling assembly with 
Arg81 and induction of arginine metabolizing enzymes.  Essential domains in Arg82 are 
indicated, specifically the inositol phosphate binding site (IP), the SSLL (ser-ser-leu-leu) 
site is catalytically important, and the aspartate stretch.  (B) The various non-catalytic 
activities of mammalian IPMK include its role in mTOR and AMPK signaling, as well as 
its function as a transcriptional co-activator for CBP, SRF, and p53.  The interaction sites 
of IPMK with its binding partners specifically involve IPMK exon 1 (mTOR, Dvl3, 
CBP), exon 3 (SRF), exon 4 (AMPK, p53, SRF), and exon 6 (AMPK, SRF).  Essential 
domains in IPMK include the IP site, ATP-binding site (ATP), and SSLL site, which are 
all required for the catalytic activity of IPMK.  The nuclear export signal (NES) and 
nuclear localization signal (NLS) are also shown.  The start sites and sequences for these 
essential domains of IPMK are as follows: IP (139-KPCIMDVKIGQKSYDPFASSEK), 
NES (170-LMEEIGFLVL), SSLL (249-YASSLLFVYEG), NLS (320-











Figure 1.3.  Non-catalytic activities of Arg82 and IPMK  
(Figure legend on previous page) 
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1.2 Regulation of IPMK  
 
Given the diverse and sometimes polar physiologic functions of IPMK, it is necessary to 
understand the regulation of the catalytic and non-catalytic activities of IPMK.  Cellular 
localization, post-translational modifications, transcriptional regulation, binding affinity 
of the catalytic sites, and the availability of interaction partners all contribute to the 
specific pathway or pathways activated by IPMK.       
 
1.2.1 Cellular localization  
 
The subcellular localization of IPMK might influence the specific activity required within 
a particular context.  IPMK contains a nuclear localization signal (NLS) and is mainly 
located in the nucleus as demonstrated by GFP-tagged IPMK (2).  Nuclear localization of 
IPMK partly requires the conventional pathway involving the interaction of importin α/β 
with the NLS.  However, NLS inactivation does not completely abrogate nuclear 
localization, suggesting that non-conventional nuclear shuttling pathways exist (64).  
 
The nuclear export receptor chromosomal maintenance 1 (CRM1), which recognizes the 
nuclear export signal (NES), regulates the cytoplasmic localization of IPMK (65).  
Additional proteins influence the nucleocytoplasmic shuttling of IPMK.  For example, 
CK2 binds and phosphorylates IPMK at the S284 site promoting nuclear uptake of IPMK 
(65).  The domains for the nuclear import and export of IPMK, as well as its catalytic 
activities are provided in Figure 1.3.  The membrane localization of IPMK also 
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modulates signaling pathways.  IPMK is required for the cellular response to Wnt3a.  
Wnt3a stimulation leads to IPMK docking onto disheveled and thereby localizes it to the 
cell membrane.  This interaction relies on the PDZ domain and C-terminal tail of Dvl3, as 
well as the N-terminal region of IPMK (33). 
 
1.2.2 Post-translational modification   
 
Post-translational modifications of IPMK are not well understood.  CK2 phosphorylates 
IPMK, which regulates localization as described in section 1.2.1 (65).  Furthermore, 
IPMK is phosphorylated in the presence of glucose (9).  This modification is required for 
IPMK-mediated inhibition of AMPK as discussed in section 1.1.3.  However, the kinase 
that phosphorylates IPMK remains to be identified.  Given the various functions of 
IPMK, elucidating the post-translational modifications of IPMK, including but also 
extending beyond phosphorylation, is required to understand the regulation of its 
functions.    
 
1.2.3 Binding affinity  
 
The soluble inositol phosphate kinase and lipid kinase activities of IPMK both require the 
same catalytic site.  Competition assays described in section 1.1.2 indicate that the lipid 
kinase activity of IPMK competes successfully with the substrates of its soluble inositol 




1.2.4 Transcriptional regulation 
 
The transcriptional regulation of IPMK also remains to be further investigated.  Chicken 
ovalbumin upstream promoter transcription factor-interacting protein 2 (Ctip2), also 
known as B cell lymphoma/leukemia 11B (Bcl11b), is a C2H2 zinc finger transcription 
factor.  It was recently identified as a putative transcription factor for IPMK in a screen 
(66).  Ctip2 was initially studied for its role in T lymphocyte differentiation and 
maintenance (67).  Mutations in Ctip2 are also associated with numerous malignancies, 
including T-acute lymphoblastic leukemia (T-ALL) and Ewing’s sarcoma (68).  The 
central nervous system roles of Ctip2 are further described in section 2.5.2.  
 
Understanding the temporal and spatial regulation of IPMK at the cellular and organ 
systems levels are crucial.  Furthermore, the regulation and role of IPMK in pathogenic 




































2.1 Clinical manifestation and epidemiology  
 
Huntington’s disease is a progressive neurodegenerative disorder first described in 1872 
by George Huntington who reported the prominent motor deficits and personality 
changes present in adult-onset HD (69).  HD is characterized by a gradual decline in 
cognitive and motor function, as well as the presence of psychiatric symptoms and motor 
signs.  Although subtle signs are present during the pre-symptomatic stage of the disease, 
the clinical diagnosis is based on extrapyramidal motor signs, such as chorea, an 
involuntary and abnormal dance-like movement (70).  Approximately 90% of HD 
patients experience chorea (71).  Additional motor signs during early stages of the disease 
include dyskinesia.  As the disease progresses, patients exhibit more debilitating motor 
signs, such as rigidity, dystonia and bradykinesia.  It is also essential to consider the 
impairment of fine motor control resulting in dysarthria and dysphagia, or speech and 
swallowing difficulties.  The progressive impairment of gross and fine motor functions is 
associated with a concomitant decline in function and quality of life (72). 
  
The cognitive decline and psychiatric symptoms also contribute substantially to the loss 
of quality of life of HD patients and often begin early prior to a formal diagnosis. 
Cognitive dysfunction includes impaired executive function such as planning, altered 
memory and learning, and diminished attention, language-related functions, and 
visuospatial functions (73).  There is also a lack of awareness of deficits, as well as 
disinhibition.  Psychiatric symptoms include anxiety, irritability, impulsivity, aggression, 
apathy, and depression (70).  Delusions, hallucinations, and psychoses have also been 
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detected in approximately 50% of patients (74).  These psychiatric symptoms are thought 
to contribute to the high suicide rate of HD patients, which was also described by George 
Huntington (69).  
 
Although HD is mainly characterized by the triad of motor, cognitive and psychiatric 
symptoms, additional systems are also affected. There is evidence of weight loss, muscle 
wasting, metabolic dysfunction, endocrine disturbance (75), as well as sleep and 






















Histopathologically, HD is characterized by striatal atrophy resulting from the selective 
loss of medium spiny neurons (MNSs), whereas the striatal interneurons remain largely 
unaffected.  MSNs comprise 90-95% of striatal neurons (77-79).  As the disease 
progresses, other brain regions become affected including the cerebral cortex, subcortical 
white matter and thalamus (80).  Within the cerebral cortex, the pyramidal neurons of the 
middle and deeper cortical layers are specifically affected (81, 82).  At the cellular level, 
inclusions containing insoluble mHtt aggregates are present in the nucleus, cytoplasm, 
and neurites of affected MSNs (83).  The neuropathological changes in the striatum, as 
well as the other subcortical nuclei that comprise the striatum, are classified according to 
severity (84) (Table 2.1).        
 
2.2.2 Basal ganglia 
 
The basal ganglia is a complex series of circuits connecting the striatum, which receives 
excitatory input from the cortex, to the internal or external segment of the globus pallidus 
(GPi or GPe), the substantia nigra pars reticulata (SNr), and the subthalamic nucleus 
(STN).  Projections from these nuclei converge on the ventral anterior (VA) and ventral 
lateral (VL) nuclei of the thalamus, which sends excitatory projections back to the 





Table 2.1.  Classification of HD striatal pathology  
 
 
Grade Striatal neuropathological features  
0 Normal 
1 Mild neuronal death and fibrillary astrocytosis 
2 Mild striatal atrophy, neuronal death and fibrillary astrocytosis 
3 Moderate striatal atrophy, neuronal death and fibrillary astrocytosis 















the STN, which sends excitatory glutamatergic efferents to the GPi.  Depending on the 
cortical area involved, the basal ganglia can modulate various functions ranging from 
motor functions to executive and limbic functions. The motor functions include the 
planning, initiation, and execution of movements, as well as motor learning (85). 
 
The motor circuit originates in the pre- and postcentral sensorimotor fields and the motor 
areas of the cortex.  It consists of two main pathways with polar effects: the direct and the 
indirect pathways, which project to two distinct populations of MSNs (figure 2.1).  Both 
MSN populations release the inhibitory neurotransmitter γ-aminobutyric acid (GABA).  
In the direct pathway, the cortex sends excitatory projections to striatal MSNs, which 
send inhibitory projections to the GPi and SNr. The GPi/SNr send inhibitory signals to 
the VA/VL complex of the thalamus, thus the thalamus is disinhibited in the direct 
pathway and provides excitatory efferents to the cortex.  Overall, the direct pathway 
facilitates movement. 
 
In the indirect pathway, a second population of striatal MSNs send efferent inhibitory 
signals to the GPe, which subsequently sends inhibitory projections to both the GPi and 
the STN.  The disinhibited GPi projects inhibitory efferents to the VA/VL complex of the 
thalamus thus reducing thalamocortical input.  The STN, which is also disinhibited, sends 
excitatory projections further activating the GPi.  The resulting inhibition of the thalamus 




Dopaminergic efferents from the substantia nigra pars compacta (SNpc) also modulate 
the direct and indirect pathways with the net effect of decreasing the inhibitory 
transmission of the basal ganglia and promoting movement.  The excitatory D1 receptors 
expressed in direct pathway MSNs stimulate the direct pathway thereby enhancing 
movement.  The inhibitory D2 receptors of the indirect pathway MSNs inhibit the 
indirect pathway thereby also facilitating movement.  
 
Huntington’s disease is a hyperkinetic disorder involving excessive movements, such as 
chorea and dyskinesia during the early stages of the disease.  This excessive movement 
reflects impaired inhibitory basal ganglia transmission due to the loss of indirect pathway 
medium spiny neurons, resulting in the disinhibition of the thalamus and facilitation of 
movement early in HD (86).  The later loss of direct pathway MSNs is associated with 
impaired movement characteristic of late-stage HD, including bradykinesia and dystonia 
(87).  The differences between these MSN subtypes may account for their different 
vulnerability in HD.  The direct pathway MSNs express Substance P, dynorphin, and D1 
dopamine receptors while the indirect pathway MSNs express enkephalin and D2 
dopamine receptors.  Furthermore, the direct and indirect pathway MSNs display 













Figure 2.1.  Basal ganglia circuitry 
In a healthy brain, the direct pathway (cortex, striatum, GPi/SNr, and thalamus) facilitates 
movement whereas the indirect pathway (cortex, striatum, GPe, STN, GPi/SNr, and 
thalamus) inhibits movement.  Dopaminergic projections from the SNpc enhance the 
direct pathway while inhibiting the indirect pathway thereby facilitating movement.  
Black arrows and red arrows indicate excitatory and inhibitory projections, respectively.  
Components of the basal ganglia represented in beige are part of the indirect pathway, 






2.3 Genetics   
 
The discovery of the genetic cause of HD, a mutation in the huntingtin gene, has led to 
significant advances in the understanding of HD pathogenesis (90).  A large collaborative 
effort involving the scientific community, specifically the HD Collaborative Research 
group (HDCR) and a Venezuelan community with a high rate of HD cases, led to 
mapping the mutation to chromosome 4p in 1983.  Ten years later, the polyglutamine 
repeat expansion in the N-terminus of the huntingtin gene was identified (69). 
 
HD is a monogenic autosomal dominant disorder.  In fact, 90% of HD is hereditary (91).   
HD is caused specifically by a poly-glutamine (CAG) triplet repeat expansion in the N-
terminus of the huntingtin gene.  Individuals with 6-35 glutamine repeats are 
asymptomatic although CAG repeats between 27 and 35 can be unstable during 
transmission.  Expansions greater than 35 repeats generally cause HD and longer repeats 
correlate with earlier disease onset (69).  In fact, juvenile-onset HD is associated with 
more than 70 repeats, as well as anticipation, which consists of polyglutamine repeat 
expansion during paternal inheritance (92).  CAG repeat lengths account for 50-70% of 
variance of age of onset.  Other factors affecting age of onset include genetic modifiers, 
such as glutamate receptor ionotropic, kainate 2 (GluR6) discussed in section 2.5.2 (72).  
 
Huntingtin is a 348-kDa protein consisting of several domains (Ross and Tabrizi, 2011). 
The N-terminal begins with a 17-amino acid stretch, also known as the N17 domain, 
which is highly susceptible to post-translational modifications.  The polyglutamine region 
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begins at the 18th amino acid and is followed by a proline-rich region, which is involved 
in protein-protein interactions and also modulates mHtt toxicity (93-95).  The remaining 
huntingtin sequence contains several interspersed HEAT repeats (huntingtin, elongation 
factor 3, protein phosphatase 2A, and yeast kinase TOR1), which form a superhelical 
structure.  These HEAT domains are also thought to be involved in protein interactions.  
The C-terminus contains the nuclear export and nuclear localization signals (72). 
 
Huntingtin undergoes several post-translational modifications.  The N17 domain is 
phosphorylated at several sites (T3, S13, and S16) modulating mHtt (96, 97).  This 
domain is also ubiquitinated and sumoylated at K6/9 and K15 (72, 98).  These 
modifications occur at the same lysine residues and are thought to compete with each 
other.  Ubiquitination promotes the ubiquitin-proteasome system-mediated degradation of 
mHtt (99) whereas sumoylation enhances toxicity (98).  
 
Additional modifications are present outside the N17 domain.  Huntingtin is 
palmitoylated by huntingtin-interacting protein HIP14 at the C214 site, resulting in the 
membrane localization of huntingtin (100).  Huntingtin is also phosphorylated at the 
S421 site by Akt (101) and serum- and glucocorticoid- induced kinase (SGK) (102), 
resulting in decreased aggregation and neuroprotection.  Lastly, huntingtin is acetylated 







2.4 Cellular dysfunction  
 
HD symptoms are evident prior to neuronal death, indicating that neuronal dysfunction 
contributes to the psychiatric, cognitive, and motor deficits characteristic of HD.  
Mechanisms associated with the loss of function of Htt and gain of function of mHtt are 
thought to contribute to neuronal dysfunction in HD 
 
2.4.1 Loss-of-function mechanisms 
 
Wild type Htt is expressed ubiquitiously in the organism.  Although it is also expressed 
through the cell, Htt is mainly localized within the cytoplasm where it associates with 
vesicles (104).  At the cellular level, a greater than 50% decrease in Htt expression results 
in impaired neurogenesis, neuronal dysfunction and death, abnormal morphology of 
cellular organelles, and impaired transport of mitochondria and vesicles containing brain-
derived neurotrophic factor (BDNF) (95, 105).  Given these various cellular roles, Htt is 
crucial for several developmental processes, including gastrulation and brain 
development (106).  In fact, Htt null mice are embryonic lethal at E8.5 (107).  
Interestingly, mHtt can compensate for the loss of Htt during development.  However, 
these MSNs containing mHtt may be more vulnerable to cellular stressors (108). 
 
2.4.2 Gain-of-function mechanisms 
 
Pathogenic forms of mHtt 
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Several pathologic forms of mHtt have been described including compact β 
configurations, toxic N-terminal cleavage products, and post-translational modifications.  
These forms of mHtt alter its localization, aggregation, and clearance resulting in 
neuronal dysfunction through several cell-autonomous mechanisms (72).  Two main 
subtypes of inclusions have been identified.  The tightly-packed fibrillary form, which 
can be phosphorylated in the N17 domain, is less cytotoxic than the loosely-packed 
globular form (109).  Furthermore, although mHtt aggregates cause cytoplasmic and 
nuclear inclusion bodies, the toxic forms consist mainly of mHtt oligomers and fragments 
(110).  These pathogenic forms of mHtt alter numerous cellular processes. 
 
Transcriptional dysregulation 
Transcriptional dysregulation may be an important pathogenic mechanism in HD (111). 
The polyglutamine rich expansion of mHtt can interact directly with DNA (112) and also 
with glutamine-rich domains on transcription factors thereby inhibiting them (111). 
These transcription factors include Ctip2 (113), as well as specificity protein 1 (Sp1) 
(114), TAFII130 (115), nuclear receptor co-repressor (N-CoR) (116), CBP (117), and 
p53 (118). mHtt may also influence transcription at a global level through interactions 
with the histone acetyltransferase domain of CBP (119, 120).   
 
Additional mHtt-mediated nuclear impairments have also been identified. Perinuclear 
inclusions disrupt the nuclear envelope.  Neurons containing these types of inclusions 
display markers associated with cyclin-dependent kinase 5 (CDK5)-induced cell cycle re-
entry, and were more susceptible to death (121).   
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Impaired protein degradation 
The ubiquitin-proteasome system (UPS) and the lysosomal pathway are the two main 
intracellular degradation pathways.  mHtt impairs both proteasomal and autophagic 
degradation resulting in the presence of additional abnormally folded proteins (122).   
 
Proteasomal degradation mainly targets cytosolic and misfolded proteins.  It requires a 
multi-step process whereby ubiquitin-activating enzyme (E1) activates ubiquitin in an 
ATP-dependent step followed by the transfer of ubiquitin to the ubiquitin-conjugating 
enzyme (E2).  E2 acts in concert with ubiquitin ligase (E3) to transfer ubiquitin to the 
substrate resulting in a polyubiquitin chain linked at the K48 residue (123).  The 
accumulation of K48-linked polyubiquitin chains in R6/2 mice and HD patients indicates 
loss of UPS function in HD (122).  
 
Lysosomal degradation, which includes macroautophagy and chaperone-mediated 
autophagy (CMA) involves the degradation of bulk cytoplasmic content (124).  
Macroautophagy requires the formation of a double-membrane vesicle around the content 
marked for degradation by K63-linked polyubiquitin (125).  These vesicles subsequently 
fuse with lysosomes resulting in the degradation of vesicular contents.  Macroautophagy 
impairment results in the accumulation of ubiquitinated aggregates (126).  K63-linked 
polyubiquitin chains also accumulate in HD patients and animal models (122).  
Furthermore, autophagy induction by rapamycin in fruit fly and murine models of HD 
protected against neurodegeneration by reducing aggregate formation and toxicity (127).   
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Chaperone-mediated autophagy specifically requires substrate recognition by heat-shock 
cognate 70 (HSC70), which binds to the lysosome-associated membrane protein 2A 
(LAMP2A) receptor and transfers the substrate to the lysosome (123).  CMA is thought 
to be up-regulated in early HD to compensate for the loss of the UPS and 
macroautophagy (128).  
 
Mitochondrial dysfunction 
Mitochondrial dysfunction is a common feature in neurodegenerative disorders.  Fewer 
mitochondria, corresponding with disease severity, have been detected in HD brain 
tissue.  Altered expression of proteins involved in mitochondrial regulation have also 
been implicated in HD.  Elevated dynamin-related protein 1 (Drp1) with concomitant 
mitofusin (MFN) depletion enhance mitochondrial fission (129).  The transcriptional co-
activator peroxisome proliferator-activated receptor γ coactivator-1 α (PGC-1α) regulates 
mitochondrial biogenesis and respiration.  Impaired transcription of PGC-1α in HD also 
results in reduced neuronal size, neurodegeneration and motor deficits (130).   
 
Mitochondrial damage has been linked to altered calcium (Ca2+) homeostasis. In fact, 
elevated cytosolic Ca2+ levels cause excess mitochondrial calcium loading resulting in 
superoxide generation, oxidative damage, and also the loss of mitochondrial membrane 
potential (131).  Mitochondrial depolarization subsequently leads to cytochorome c 
release and cell death (132).  The various effects of mHtt in HD collectively alter cellular 
metabolism and increase neuronal vulnerability to cellular stressors, such as a reactive 
oxygen species (ROS), leading to neuronal death.   
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2.5 Striatal selectivity  
 
2.5.1 Non-cell autonomous mechanisms 
Similar to other progressive neurodegenerative disorders, HD targets a particular 
neuronal population, specifically the striatal MSNs.  Since mHtt is ubiquitously 
expressed, numerous cell-autonomous and non-cell autonomous hypotheses have been 
proposed to explain the striatal selectivity of HD.   
 
Excitotoxicity 
Corticostriatal excitotoxicity was one of the earliest mechanisms posited for the striatal 
selectivity observed in HD.  Intrastriatal glutamate injections resulting in excitotoxicity 
demonstrated the increased vulnerability of MSNs compared to the interneurons (133).  
The receptor composition and localization of MSNs contribute to their susceptibility.  
Synaptic N-methyl-D-aspartate receptor (NMDAR) activate CREB, resulting in 
neuroprotection.  However, the stimulation of extrasynaptic NMDAR inhibit the pro-
survival effects of CREB (134, 135).  Polymorphisms of the GluR6 kainate receptor also 
contribute to age of onset of HD (136).   
 
Excitotoxicity is linked to altered calcium homeostasis and mitochondrial dysfunction 
(discussed in section 2.4.2).  Several types of glutamate receptors, including mGluR1/5 
and NR2B, appear to mediate the increase in cytosolic calcium levels in HD.  Elevated 





Neurotrophic factors are required for neuronal survival.  Decreased transcription of 
neurotrophic factors, impaired transport of these factors, loss of cortico-striatal 
projections, and altered receptor signaling all contribute to reduced neurotrophic factor 
signaling.  
 
The cortex supplies much of the BDNF required for the development, maintenance, and 
plasticity of MSNs through anterograde transport (138).  BDNF specifically binds to the 
receptor tyrosine kinase tropomyosin receptor kinase B (TrkB), resulting in receptor 
dimerization and autophosphorylation.  The subsequent phosphorylation of additional 
tyrosine residues creates docking sites for adapter proteins thereby coupling TrkB to 
intracellular signaling cascades, which include the PI3K/Akt, Ras/ERK, and PLCγ1 
pathways (139).  The two main isoforms of TrkB include the full-length isoform, which 
contains a tyrosine kinase domain and a truncated isoform lacking the catalytic domain.  
This truncated isoform can act as a dominant negative, adding another layer of 
complexity to this signaling pathway (140).  
 
mHtt-mediated transcriptional dysregulation results in decreased production of cortical 
BDNF (141).  mHtt also impairs the anterograde transport of BDNF vesicles (142).  More 
recently, impaired TrkB signaling, independent of BDNF alterations, has been 
demonstrated in HD (143).  Thus, the BDNF-TrkB signaling pathway is severely 





Several non-neuronal mechanisms of MSN-selectivity have also been suggested.  
Microglial activation begins during the prodromal stages of HD and correlates with 
disease severity (144, 145).  In fact, mHtt expression in glial cells causes neuronal 
excitotoxicity in a co-culture model (146).  The release of cytokines is also thought to 
contribute to neuronal death (147).  Similarly, mHtt expression in astrocytes cause motor 
deficits and reduced survival in vivo.  One possible mechanism involves the mHtt-
mediated inhibition of Sp1 thereby impairing glutamate transporter expression in 
astrocytes (148).   
 
Thus, numerous non-cell autonomous mechanisms involving corticostriatal projections, 
astrocytes, and microglia contribute to the complex network that results in neuronal 
dysfunction and death.  These mechanisms also account for the striatal selectivity of HD.  
 
2.5.2 Cell autonomous mechanisms 
Altered expression or activity of striatal-enriched proteins may provide additional clues 
to the cell-autonomous mechanisms contributing to the striatal selectivity of HD.  
Numerous striatal-enriched genes have been identified and the majority are decreased in 
R6/1 mice.  These genes belong to specific functional groups, including proteins involved 
in transcription, excitotoxicity, axon growth and guidance, synaptic function, 
neurotransmitter receptors, and G-protein signaling (149).  Two striatal-enriched proteins, 





The transcription factor Ctip2 is enriched in the striatum and is also expressed in other 
regions of the brain such as the cortex and hippocampus (150).  Within the striatum, 
Ctip2 is specifically expressed in MSNs and is required for the differentiation of MSNs 
as well as the patch-matrix organization of the striatum (151).  Ctip2 is also expressed in 
the anterior neocortex throughout the cortical plate during development (152) where it is 
involved in corticospinal motor neuron axon growth and fasciculation (150, 153).  
 
Interestingly, Ctip2 is depleted in the R6/1 animal model of HD and in post-mortem 
striatal samples from HD patients (113, 149).  Furthermore, over-expression of Ctip2 in a 
cellular model of HD appears to rescue the metabolic activity deficit in these cells (113).  
Thus, Ctip2 and its downstream targets could also account for the striatal and MSN-
specific disease pathology in HD.  
 
Ctip2 generally results in transcriptional repression when interacting with COUP-TF 
family members (154).  However, it can also act as a transcriptional co-activator.  A 
genome-scale chromatin immunoprecipitation followed by massively parallel sequencing 
(ChIP-Seq) and genome-wide expression profiling led to the identification of several 
putative targets of Ctip2 in immortalized wild-type striatal cells over-expressing Ctip2.  
IPMK was identified as a potential target of Ctip2 in this screen (66).   
 
Given the various targets of Ctip2 and its functions as a transcriptional repressor and 
transcriptional co-activator, it is necessary to understand the regulation of Ctip2 
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expression and activity.  The histone deacetylase sirtuin 1 (SIRT1) interacts with Ctip2 
and specifically enhances transcriptional repression mediated by Ctip2 (155).  In 
addition, Ctip2 is a substrate for sumoylation (156).  However, the effect of this 
modification remains to be investigated.   
 
Rhes 
Rhes was first identified as a guanosine triphosphate (GTP)-binding protein (157).  In 
addition to this function, Rhes is involved in sumoylation, a process similar to 
ubiquitination, in which small ubiquitin-like modifier (SUMO) is conjugated to a 
substrate (158).  Sumoylation is involved in numerous neuronal functions ranging from 
synapse formation to neurotransmitter release and synaptic scaling (158).   
 
Aberrant sumoylation has been implicated in several diseases, including HD.  Rhes has 
been shown to enhance cytotoxicity in cellular models of HD (157, 159).  Furthermore, 
Rhes knockout mice are protected from 3-nitroproprionic (3-NP)-induced striatal 
degeneration (160) and Rhes-deleted transgenic HD mice also show a delayed onset of 
behavioral symptoms (161).  At the molecular level, Rhes acts as an E3 ligase for the 
sumoylation of mHtt resulting in decreased protein aggregation, increased levels of 
soluble mHtt, and cytotoxicity (159).  Interestingly, mutant Htt is ubiquitinated and 
sumoylated at the same lysine residue resulting in neuroprotection and enhanced 





2.6 Animal models 
 
Early models of HD involve neurotoxin-based striatal lesions.  The glutamate agonists, 
kainic acid and quinolinic acid, both result in glutamatergic excitotoxity (162-164).  
Mitochondrial toxins such as 3-NP, also cause bilateral striatal lesions (165). 3-NP 
inhibits complex II of the mitochondrial electron transport chain (166).  These 
neurotoxin-mediated models of HD have helped elucidate several mechanisms 
contributing to the striatal pathology of HD, specifically excitotoxicity and mitochondrial 
dysfunction.  However, these models are incomplete due to the acute nature of the lesion 
(167).  
 
The discovery of mHtt led to the generation of numerous rodent models of HD. These 
models differ based on several features including: 1) full length mHtt versus mHtt 
fragment, 2) length of CAG repeats, 3) transgene versus knock-in into endogenous Htt 
locus, 4) human or mouse Htt, 5) cDNA versus genomic DNA which carries introns and 
regulatory sequences, and lastly, 6) endogenous Htt promoter versus another promoter.  
The different features of these models influence neuropathological changes in the animal, 
as well as motor deficits and survival.  Various behavioral tests are used to assess the 
severity of motor dysfunction, which include locomotor activity deficit, progressive 
decline in rotarod activity, lengthened time to cross balance beam, and gait abnormalities 




The R6/2 transgenic model of HD involves the expression of the N-terminal fragment of 
mHtt, specifically exon 1, downstream of a human Htt promoter.  This is the most severe 
model of HD with a lifespan of approximately 13 weeks due to the large repeat number 
and the use of the N-terminal fragment, which is more toxic than full-length mHtt.  In 
fact, neuropathological changes such as striatal atrophy are detected as early as six weeks 
of age in this model (168).  Several motor deficits such as rotarod and open field 
performance are evident even earlier, at approximately five weeks of age (169).  
 
The zQ175 knock-in model consists of full-length human mHtt downstream of the 
endogenous mouse Htt promoter (170).  These mice have a longer survival period 
ranging from 76-104 weeks, reflecting the milder genetic modifications used to generate 
this model.  Behavioral deficits are also more progressive in this model of HD.  In fact, 
impaired rotarod performance is detected at approximately 30 weeks.   
 
There are also several non-rodent models of HD, which present several advantages and 
disadvantages.  Invertebrate models of HD, specifically Caenorhabditis elegans and 
Drosophila melanogaster, allow for rapid initial studies.  However, findings from these 
models require further testing in mammalian models of HD.  Non-human primate models 
and larger mammalian models such as pigs and sheep facilitate the study of drug delivery 
mechanisms, including the delivery of viral vectors and anti-sense oligonucleotides. 
However, these models take longer to generate and study due to the more gradual 




2.7 Therapeutic directions  
 
Knowledge of the genetic mutation causing HD, as well as the correlation between repeat 
number and age of onset, has allowed for predictive genetic testing.  Therefore, 
abolishing mHtt pathology prior to disease onset could potentially cure HD patients.   
Furthermore, HD therapies might not only delay disease progression, but could also 
reverse symptoms.  Blocking mHtt expression in a tetracycline-regulated HD model 
eliminated inclusions and rescued motor phenotype (171).   
 
Potential drugs targeting huntingtin aggregation, mitochondrial dysfunction, 
excitotoxicity, transcriptional impairment, inflammation and oxidative stress appear to 
increase survival in animal models of HD and reduce neuropathological changes (120, 
172-175).  However, human clinical trials will ultimately determine the efficacy of these 
drugs.  More recent studies have focused on developing mHtt-lowering therapies, such as 
the mHtt allele specific anti-sense oligonucleotides (ASOs) (176).  Lastly, the potential 
benefits of endogenous stem cells, as well as their differentiation and integration are 
being investigated (177).  However, further research is needed to assess potential 
neuropathologic changes in the newborn neurons over time.   
 
The discovery of the genetic cause of mHtt has led to the elucidation of a vast network of 
signaling pathways and cellular processes that contribute to the pathophysiology of HD.  
Understanding the central players in this network and the striatal selectivity of HD will 




























3.1 Objectives  
 
Various processes are thought to contribute to the selective dysfunction and death of 
MSNs in Huntington’s disease. Given the mHtt-mediated alterations in the expression 
and function of the striatal-enriched protein Ctip2, which has been identified as a putative 
transcription factor for IPMK, we hypothesized that IPMK might also play a role in the 
pathophysiology of HD.  IPMK has been shown to exert pro-survival and pro-death 
effects through its numerous catalytic and non-catalytic functions, suggesting that it could 
be a central component in the vast signaling network contributing to cellular dysfunction 
in HD.  Thus, we sought to elucidate the role of IPMK in neurodegeneration.  The main 
objectives of this study include the following: 1) characterize the expression of IPMK in 
HD, 2) identify the molecular mechanisms regulating IPMK expression, 3) determine the 
signaling targets of IPMK involved in HD, and 4) study the therapeutic potential of 
IPMK in vivo. 
 
3.1.1 Characterization of IPMK expression in HD  
 
Since IPMK is likely regulated by Ctip2, which is depleted in HD, IPMK expression is 
also expected to be altered in HD.  IPMK expression was characterized in cell models of 
HD, animal models of the disease, and post-mortem tissue samples from HD patients.  
Furthermore, catalytic activities unique to IPMK were investigated to further confirm 




3.1.2  Identification of molecular mechanisms regulating IPMK  
 
We sought to confirm whether IPMK is indeed a transcriptional target of the striatal-
enriched transcription factor Ctip2.  Furthermore, since numerous cellular mechanisms 
are altered in HD, we also examined whether IPMK protein stability is altered.  
 
3.1.3 Identification of the role of IPMK in neuronal dysfunction  
 
IPMK is involved in numerous cellular functions yielding pro-apoptotic and pro-survival 
effects depending on the signaling pathways activated.  Thus, it was necessary to 
determine whether alterations in IPMK expression are pathogenic or compensatory.  
Given the multi-functional nature of IPMK, the specific downstream signaling pathways 
involved in HD pathogenesis were also examined.  
 
3.1.4 Investigation of the effect of IPMK in an animal model of HD  
 
The cellular model of HD indicated that loss of IPMK is pathogenic in HD.  Furthermore, 
restoration of IPMK improved cellular metabolism.  Thus, we investigated whether 
down-regulation of IPMK, and conversely, intrastriatal delivery of IPMK in an animal 






3.2 Materials and methods  
 
Cell cultures  
The immortalized striatal cell lines STHdhQ7/Q7 (Q7), STHdhQ111/Q111 (Q111), and 
STHdhQ7/Q111 (Q7/Q111) express endogenous wild type huntingtin (Htt) and mutant 
huntingtin (mHtt) with 7 or 111 polyglutamine repeats, respectively.  These cell lines 
were provided by M. MacDonald (Department of Neurology, Massachusetts General 
Hospital, Boston).  The cells were maintained at 33oC in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum, 2mM L-glutamine, 400 
μg/ml geneticin, and antibiotics (penicillin and streptomycin).  Experiments were 
performed without geneticin.  Cells beyond passage 15 were not used for experiments.  
HEK293 cells were grown at 37oC in DMEM supplemented with 10% fetal bovine 
serum, 2mM L-glutamine, and antibiotics.   
 
Reagents 
The Q7 and Q111 cells were transfected using Lipofectamine 2000 (Invitrogen).  
HEK293 cells were transfected with Polyfect (Qiagen).  Ctip2 siRNA and scrambled 
siRNA (Santa Cruz) were used at a concentration of 50 pmol and 100 pmol.  For 
translational blocking, cells were treated with 30 μg/ml cycloheximide (Sigma).  Q7 and 
Q111 cells were treated with MG132 (carbobenzoxy-Leu-Leu-leucinal) and bafilomycin, 
inhibitors of proteasomal degradation and lysosomal degradation, respectively, for 13 h at 





Animals were housed and cared for in accordance with the National Institutes of Health 
guide for the Care and Use of Laboratory Animals and approved by the Johns Hopkins 
University Animal Care and Use Committee (JHU ACUC).  Animals were kept on a 12 h 
light/dark cycle and provided food and water ad libitum.  The R6/2 mice (B6CBA-
Tg(HDexon1)62Gpb/1J), a transgenic model of HD which expresses exon 1 of human 
Htt, were purchased from Jackson Laboratory.  This line carries approximately 150 
polyglutamine repeats.  The breeding strategy involved ovarian transplant hemizygous 
females and B6CBAF/1J males.  Only F1 R6/2 and non-carrier sibling males were used 
for the experiments.  The zQ175 mice, obtained from the CHDI foundation, is a knock-in 
model of Huntington’s disease and contains one chimeric human/mouse exon 1 allele 
with approximately 190 polyglutamine repeats (170).  IPMK gene knockout is embryonic 
lethal in mice (42).   
 
IPMK floxed (IPMKfl/fl) mice, in which the loxP sites flank exon 6 of IPMK, were 
generated by Ozgene.  Neuron-specific conditional IPMK knockouts were generated by 
breeding the IPMKfl/fl animals with Nestin-cre, producing Nestin-cre; IPMKfl/fl animals 
with littermate IPMKfl/fl controls.  Animals heterozygous for IPMK (IPMK Het) were 
also generated by Ozgene.  Male IPMK Het animals were bred with ovarian transplant 






Post-mortem brain tissues 
Striatal tissues from control and HD patients were obtained from J. Troncoso and O. 
Pletnikov (Brain Resource Center, Johns Hopkins University).  Information on patient 
age at death, gender, HD grade and post-mortem delay (PMD) are provided in Table 3.1.  
 
Plasmids 
The plasmids encoding wild type IPMK (IPMK WT), kinase dead IPMK (KASA), and 
the Arabidopsis thaliana ortholog atIPK2β, as well as the wild type IPMK fragments 
were previously described (7, 10, 12).  IPMK displays a soluble inositol phosphate kinase 
(IPK) activity, which is present in mammalian IPMK as well as atIPK2β.  Only 
mammalian IPMK exhibits a lipid kinase (PI3K) activity.  Furthermore, mammalian 
IPMK interacts with various proteins resulting in non-catalytic activities.  Mutation of 
IPMK at K129A-S235A (IPMK KASA) abolishes both catalytic activities of IPMK, 
while retaining its non-catalytic activities.  The activities of IPMK WT, IPMK KASA, 
and atIPK2β are summarized in Table 3.2.  The CTIP2 plasmid was purchased from 
Origene.  The N-terminal fragments of wild type Htt (N171-18Q) and mHtt (N171-82Q) 
were previously described (159).  pcDNA3-AKT-PH-GFP was a gift from Craig Montell 










Table 3.1.  Post-mortem control and HD striatal tissues   
 
 
Sample Grade Gender Age (yrs) PMD (hrs) 
1 Control  Male 60 6 
2 Control Female 68 11 
3 Control Male 64 12 
4 Control Male 42 19 
5 Control Female 46 24 
6 HD Grade 4 Male 63 5 
7 HD Grade 4 Male 63 15 
8 HD Grade 4 Male 41 21 
9 HD Grade 4 Male 41 8 
10 HD Grade 3 Female 50 4 
11 HD Grade 3 Male 43 23 













Table 3.2.  Catalytic and non-catalytic activities of IPMK mutant and ortholog 
 
 
 IPMK WT IPMK KASA atIPK2β 
IPK activity + - + 
PI3K activity + - - 


















Quantitative real-time PCR 
RNA was isolated from Q7 and Q111 cells using the RNEasy mini kit (Qiagen).  
Quantitative real-time PCR was performed in quadruplicates using the TaqMan RNA-to-
Ct 1-step kit and the StepOnePlus real-time PCR system (Life Technologies).  TaqMan 
probes for mouse IPMK and mouse Ctip2 were used.  Data were normalized to β-actin. n 
= 3 for all real-time PCR experiments. 
 
Western blotting 
Q7 and Q111 cells were lysed in a buffer containing 50mM Tris HCl (pH 7.5), 150mM 
NaCl, 1% triton x-100,10% glycerol and protease and phosphatase inhibitors (standard 
lysis buffer).  Animals were euthanized with CO2 in accordance with JHU ACUC 
protocol.  The striatum of wild type (WT) and R6/2 mice were collected at 13 weeks.  
The striatum of WT and zQ175 mice were harvested at 12 months.  These were 
homogenized in standard lysis buffer using a hand-held homogenizer.  Post-mortem 
human tissue was homogenized in RIPA lysis and extraction buffer.  Cell lysates and 
brain homogenates were centrifuged at 14,000 rpm for 30 min and the supernatant was 
collected for Western blotting.  Mouse IPMK antibody, which detects a 47-kDa band, 
was produced in-house (Covance), and was previously described (7).  This antibody also 
binds non-specifically thereby generating several additional bands, including a yet 
unidentified 49-kDa protein.  Additional antibodies used include human IPMK 
(Genetex), total Akt, phospho-Akt (T308) and phospho-Akt (S473) (Cell Signaling 
Technology), and IPPK, GAPDH and β-actin (Santa Cruz).  The secondary anti-rabbit 
and anti-mouse antibodies were purchase from GE Healthcare.  Densitometric analysis of 
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Western blot bands was performed using ImageJ and normalized to β-actin, GAPDH, or 
total Akt.  n = 4 for the cycloheximide studies and IPMK overexpression studies.  n = 3 
for all experiments. 
 
Co-Immunoprecipitation 
Cells were lysed in standard lysis buffer 24 h after transfection.  Lysates were further 
homogenized using a 25-gauge needle and then centrifuged.  Samples were pre-cleared 
using rabbit IgG-agarose (Sigma) for 1 h.  Following protein measurement, supernatant 
containing 500 μg of protein were incubated overnight with EZview Red c-myc-agarose 
(Sigma).  The beads were washed five times with wash buffer (50mM Tris HCL [pH 7.5], 
300mM NaCl, 1% Triton X-100 and 10% Glycerol).  Protein was eluted by boiling in 2x 




The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, which 
measures mitochondrial succinate dehydrogenase activity, was used to assess 
mitochondrial metabolic activity.  Q7 and Q111 cells were plated at a density of 2x105 
cells/well and transfected in triplicates after 16 h.  After 48 hours, cells were treated with 
250 μg/ml MTT and incubated at 33oC for 1.5 hours.  After removal of the media, 2 ml 
DMSO was added to each well to dissolve the formazan crystals.  The absorbances at 570 
nm and 630 nm were determined using a SpectraMax M3 plate reader (Molecular 
Devices) and Softmax Pro software.  n = 4-6 for MTT experiments.  
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Inositol polyphosphate measurement  
Q7 and Q111 cells were plated in 6-well dishes.  After reaching 60% confluence, the 
cells were labeled with 200 μCi [3H]inositol (Parkin Elmer) for three days.  Soluble 
inositol phosphates were extracted using an acid lysis (0.6M perchloric acid and 2mM 
EDTA), neutralized with 1M K2CO3, and then centrifuged.  1mM EDTA was added to 
the supernatant.  Following extraction, the inositol phosphates were resolved by anion-
exchange HPLC as previously described (51).  The soluble inositol phosphates were 
detected using a scintillation counter.  IP4, IP5, and IP6 levels were normalized to myo-
inositol levels in each sample.  n = 6 for all inositol phosphate quantitation experiments.  
 
Cloning Strategy 
The myc-tagged IPMK sequence was cloned into the pAAV-SYN-EGFP-T2A vector 
(provided by Vector Biolabs) (Figure 3.1A) and subsequently subcloned into the pAAV-
E/SYN-WPRE vector (provided by Vector Biolabs) (Figure 3.1B).  Primers containing 
the EcoRV and XbaI restriction sites in the 5’ and 3’ primers, respectively, were used to 
amplify IPMK (Table 3.3).  Following EcoRV and XbaI digestion of the insert and the 
pAAV-SYN-EGFP-T2A vector, the insert was ligated downstream of the EGFP-T2A 
sequence (Figure 3.1A).  The T2A linker is a self-cleaving peptide that enables separation 
of EGFP from IPMK; thus enabling visualization of cell transduction without altering 
IPMK function.   
 
The E/SYN hybrid promoter consists of a 400-bp CMV enhancer (designated as E) and 
450-bp human Synapsin I promoter fragment (SYN), which results in approximately 2-4 
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fold higher expression than the parental SYN promoter.  In fact, the pAAV-SYN-EGFP-
T2A vector takes about four weeks to express when injected in mouse brain, whereas the 
pAAV-E/SYN-WPRE vector requires about two weeks for expression post-injection 
(data not shown).  Therefore, the EGFP-T2A-IPMK sequence was subcloned into the 
pAAV-E/SYN-WPRE vector using the NheI and AgeI restriction sites (Figure 3.1B).  
Correct insertion of IPMK was verified at all stages of cloning using the IPMK forward 
and reverse sequencing primers (Table 3.3).  The E/SYN forward, EGFP forward and 
WPRE reverse sequencing primers confirmed correct insertion of the EGFP-T2A-IPMK 
sequence in the final vector.  Vector Biolabs generated the adeno-associated virus 


















Figure 3.1.  AAV vector cloning strategy  
(Figure on following page) 
 
(A) IPMK was inserted within the multiple cloning site of pAAV-SYN-EGFP-T2A using 
the EcoRV and XbaI restriction enzyme sites.  (B) EGFP and IPMK were subcloned into 








Figure 3.1.  AAV vector cloning strategy  































Sequencing primers  
IPMK forward CCTGGCCCAAGATCTGAAT 
IPMK reverse AGACCGAGGAGAGGGTTAGG 
E/SYN forward ACTCAGCGCTGCCTCAG 
WPRE reverse AGCAATAGCATGATACAAAGGCA 




AAV2 containing either a control empty vector or IPMK were generated by Vector 
BioLabs at a titer of 3.1x1012 GC/ml.  IPMK is expressed downstream of an E/SYN 
promoter and an EGFP cassette followed by a T2A linker.  EGFP is cleaved from IPMK 
once the proteins are expressed.  Three-week-old male mice were anesthetized using 300 
μl avertin (20 mg/ml solution).  The zero coordinates were set at Bregma.  Two holes 
were drilled and the virus was delivered using a Hamilton syringe with a 33-gauge blunt-
tip needle bilaterally.  The needle was lowered at a rate of 1 mm/min into the striatum 
(anterior (A) -0.8, lateral (L) 2, ventral (V) -3.7), pulled back to (A -0.8, L 2, V -3.5), and 
left in place for 2 min.  One μl virus was injected at this site and three additional sites 
along the Z-axis (A -0.8, L 2, V -3.3), (A -0.8, L 2, V -3.1), (A -0.8, L 2, V -2.9) for a 
total of 4 μl virus in each striatum.  After the last injection and 2-min hold, the needle 
was raised up 0.2 mm and left in place for 5 min.  The needle was then withdrawn at 0.5 
mm/min.   
 
Immunofluorescence and immunohistochemistry 
Male mice, which received AAV2 injections, were anesthetized with 100 mg/kg 
pentobarbital and perfused transcardially with 4% paraformaldehyde (PFA) at 5 weeks 
and 13 weeks of age.  Brains were extracted, post-fixed overnight in 4% PFA, and cryo-
protected in 30% sucrose.  40-µm thick free-floating sections were harvested with a 
microtome.  EM48 (Millipore) and glial fibrillary acidic protein (GFAP) (Abcam) 
immunohistochemistry were detected using ABC vectastain (Vector Labs).  The number 
and size of aggregates were quantified using ImageJ.  Nissl staining was performed using 
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a previously described standard protocol (179).  For immunofluorescence, the sections 
were mounted with ProLong Gold Antifade reagent with DAPI (Life Technologies) and 
visualized using a Zeiss LSM 510 confocal microscope.  
 
Behavior assays 
Animals were tested at 6, 8, and 10 weeks of age, except gait analysis, which was 
performed at 10 weeks of age only.  Only male animals were used unless otherwise 
indicated.  All behavior assays were performed blind to virus treatment.  For body 
weights for IPMK down-regulation studies, n = 8 for wild type, n = 7 for IPMK Het, n = 
6 for R6/2, and n = 5 for R6/2;IPMK Het animals.  Male and female animals were 
included for survival: n = 18 for wild type, n = 11 for IPMK Het, n = 13 for R6/2, and n = 
12 for R6/2;IPMK Het.  For body weight in IPMK overexpression studies, n = 10 (wild 
type with control virus), n = 9 (wild type with IPMK virus), n = 17 (R6/2 with control 
virus), and n = 13 (R6/2 with IPMK virus).  For survival, n = 10 (wild type with control 
virus), n = 11 (wild type with IPMK virus), n = 11 (R6/2 with control virus), and n = 11 
(R6/2 with IPMK virus).   
 
Open field 
Locomotor activity was assessed during the wake cycle using open field activity 
chambers with infrared photo beams (San Diego Instruments).  Data was collected over 1 
h following a 30-min acclimatization period.  Horizontal and vertical activities were 
automatically recorded as beam breaks.  For open field, n = 9 (wild type with control 
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virus), n = 10 (wild type with IPMK virus), n = 11 (R6/2 with control virus), and n = 12 
(R6/2 with IPMK virus).  These tests were performed in the dark.   
 
Balance beam and rotarod 
Motor coordination and balance was assessed using rotarod and the balance beam task.  
For rotarod, mice were trained for 10 min at constant speed.  An accelerating protocol 
was then used and repeated three times at each time point.  For rotarod, n = 7 (wild type 
with control virus), n = 10 (wild type with IPMK virus), n = 11 (R6/2 with control virus), 
and n = 9 (R6/2 with IPMK virus).  For the balance beam task, the time to traverse a 60 
cm long wooden rod (50 cm above ground) away from a light source was recorded.  
Three measurments were taken for each animal.  n = 7 (wild type with control virus), n = 
10 (wild type with IPMK virus), n = 9 (R6/2 with control virus), and n = 9 (R6/2 with 
IPMK virus).  The balance beam tests were performed in the dark.  For IPMK down-
regulation rotarod studies, n = 7 for wild type, n = 7 for IPMK Het, n = 5 for R6/2, and n 
= 5 for R6/2;IPMK Het.  
 
Composite score 
Mice were evaluated for hindlimb clasping, ledge walking, kyphosis, and gait to obtain a 
composite phenotype score (180).  A score of three is given for the worst performance in 
each category (for a maximum total score of 12).  The wild type mice received a perfect 
score of 0.  n = 9 (wild type with control virus), n = 9 (wild type with IPMK virus), n = 




Gait analysis  
Gait analysis was performed using the footprint test.  Hindpaws and forepaws were 
painted with blue and red, respectively.  Animals walked on paper lining the floor of an 
elongated box starting from a light source at one end to a dark box at the other end.  
Three stride length measurements were taken for each animal.  n = 6 (wild type with 
control virus), n = 9 (wild type with IPMK virus), n = 10 (R6/2 with control virus), and n 
= 7 (R6/2 with IPMK virus).   
 
Statistical analysis 
Statistical analysis was performed using Excel software (Analysis ToolPak).  Student’s t-
test and single-factor ANOVA were performed.  All error bars represent ± SEM.  













3.3 Results   
 
3.3.1 IPMK protein is depleted in HD striatum  
 
A useful model of HD is the striatal progenitor cell line with 111 glutamine repeats 
STHdhQ111/Q111 (Q111 or Q111/Q111) and the control cell line with 7 glutamine repeats 
STHdhQ7/Q7 (Q7 or Q7/Q7) (181).  IPMK protein is depleted by 75% in Q111 cells 
(Figure 3.2A).  A similar loss of IPMK is also detected in STHdhQ7/Q111 (Q7/Q111) 
heterozygous cells suggesting that one allele of mHtt is sufficient to deplete IPMK 
protein levels (Figure 3.2B).  The deficit in IPMK expression appears to reflect, at least in 
part, defective transcription, as IPMK mRNA levels are reduced by 40% in Q111 cells 
(Figure 3.2C).   
 
We next sought to determine whether the catalytic products of IPMK are altered in this 
cell model of HD.  IPMK produces the soluble inositol phosphates IP4 and IP5, which are 
both depleted in Q111 cells by 75% and 85%, respectively (Figure 3.3A and Figure 
3.3B).  IP5 production is entirely dependent on IPMK activity whereas IP4 and PIP3 can 
also be produced by IP3K and the p110 PI3K, respectively. Thus, the reduction in IP5 
production is consistent with the loss of IPMK protein in Q111 cells.  The IP4 peak 
contains Ins(1,3,4,5)P4 and Ins(1,4,5,6)P4.  Ins(1,3,4,5)P4 is generated by IPMK, as well 
as IP3K, which could account for the lower decrease in IP4 levels relative to the reduction 









Figure 3.2.  Loss of IPMK protein and mRNA in a cellular model of HD. 
(A) IPMK protein levels are decreased in Q111 cells.  Bars represent means ± SEM 
normalized to β-actin (n=3).  **p<0.01 relative to Q7 cells.  (B) IPMK protein levels are 
similarly decreased in Q7/Q111 cells.  (C) IPMK mRNA levels are reduced in Q111 
cells.  Bars represent means ± SEM normalized to β-actin mRNA (n=3).  **p<0.01 









Figure 3.3.  Inositol polyphosphate production in a cellular model of HD. 
(A) IP4 and IP5 levels are depleted in Q111 cells while IP6 levels remain normal.  Bars 
represent means ± SEM disintegrations per min (D.P.M.) normalized to myo-inositol 
levels (n=6).  *p<0.05 and **p<0.01 relative to Q7 controls.  (B) Representative raw 
scintillation data showing D.P.M. per fraction.  The IP4, IP5, and IP6 peaks are indicated.  
(C) IPPK levels are elevated in Q111 cells.  Bars represent means ± SEM normalized to 





IPPK, are unaltered. This is likely due to the 45% increase in IPPK protein expression in 
Q111 cells (Figure 3.3C).   
 
The R6/2 transgenic murine model of HD involves about 150 glutamine repeats (168).  
We examined IPMK levels in the striatum of R6/2 mice, as this portion of the brain is 
most prominently affected in HD (182).  Striatal IPMK protein levels are reduced about 
65% in R6/2 striatum at 13 weeks of age (Figure 3.4A).  The R6/2 mice are already 
symptomatic by 13 weeks.  A similar loss is detected in the cortex and hippocampus of 
R6/2 mice, but not in the cerebellum, which remains largely unaffected in HD (Figure 
3.4B).  The zQ175 knock-in model of HD (170) displays a similar decrease in IPMK 
protein expression in the striatum (Figure 3.4C).  Since the zQ175 model is a more 
slowly-progressing model of HD relative to the R6/2 model, changes in IPMK protein 
levels are not detectable until 12 months of age.    
 
The IPMK antibody detects an undetermined band with an approximate molecular weight 
of 49 kDa.  Interestingly, the expression of this unknown protein appears to be decreased 
in the cortex, hippocampus, and cortex of R6/2 animals, while remaining stable in the 
cerebellum (Figure 3.4A and Figure 3.4B).   
 
Most importantly, IPMK levels are diminished by 75% in post-mortem HD striatal 
tissues relative to control (Figure 3.5).  IPMK protein was similarly altered in stage III 







Figure 3.4.  IPMK protein levels are reduced in murine models of HD 
(A) 13-week-old R6/2 striatal samples contain less IPMK than littermate controls.  Bars 
represent means ± SEM normalized to β-actin (n=3).  *p<0.05 relative to wild type.  (B) 
IPMK protein levels are depleted in the cortex and hippocampus of R6/2 mice, but not 
the cerebellum.  Bars represent means ± SEM normalized to β-actin (n=4).  *p<0.05 
relative to wild type control.  (C) IPMK levels are also decreased in the zQ175 knock-in 
mouse model of HD at 12 months of age.  Bars represent means ± SEM normalized to β-









Figure 3.5.  IPMK protein levels are decreased in post-mortem HD striatal tissues. 
IPMK protein is decreased in post-mortem HD striatum.  The arrow points to the upper 
band.  Bars represent means ± SEM normalized to GAPDH (n=5 for control group and 









3.3.2 Regulation of IPMK at the transcriptional level   
 
IPMK protein levels are significantly decreased in HD.  Therefore, we sought to elucidate 
the molecular mechanisms regulating IPMK at the transcript and protein levels.  The 
striatal-enriched protein Ctip2 was recently revealed as a putative transcription factor for 
IPMK (66).  Accordingly, we explored its relevance to HD.  We confirm the loss of Ctip2 
in R6/2 striatum (Figure 3.6A).  We also detect a similar decrease in the cortex and 
hippocampus of R6/2 mice, but not the cerebellum, which does not express Ctip2 (Figure 
3.6B).  These results are consistent with previous reports describing altered expression of 
Ctip2 in the R6/1 model of HD, as well as in HD patients (113). 
 
We next sought to confirm whether Ctip2 is in fact a transcriptional regulator for IPMK.  
Depletion of Ctip2 in Q7 cells using 100 pmol Ctip2 siRNA for 96 h reduces IPMK 
levels by about 60% (Figure 3.7A).  Due to the low baseline levels of IPMK in the Q111 
cells, we were unable to detect the effect of Ctip2 down-regulation on IPMK expression 
in these cells (data not shown).  Conversely, overexpression of Ctip2 for 48 h reverses the 
loss of IPMK protein in Q111 cells, restoring them to normal values, but does not alter 
IPMK levels in Q7 cells (Figure 3.7B).  Interestingly, we also observed a similar increase 
in the 49-kDa unknown protein when overexpressing Ctip2 in Q111 cells.  These 
experiments involving the down-regulation and up-regulation of Ctip2 in Q7 and Q111 
cells are consistent with its role as a transcription factor for IPMK.  Thus, IPMK 
depletion in this cellular model of HD occurs in part at the transcriptional level through 







Figure 3.6.  Transcription factor Ctip2 is depleted in HD 
(A) Ctip2 protein levels are reduced in the R6/2 striatum relative to wild type (WT) mice.  
Bars represent means ± SEM normalized to β-actin (n=3).  *p<0.05 relative to wild type.  
(B) Ctip2 protein levels are also reduced in the cortex and hippocampus of R6/2 mice. 
Ctip2 is not expressed in the cerebellum.  Bars represent means ± SEM normalized to β-










Figure 3.7.  Ctip2 regulates IPMK expression   
(A) Ctip2 knock-down resulted in decreased IPMK expression.  Bars represent means ± 
SEM normalized to β-actin (n=3).  *p<0.05 relative to scrambled siRNA control.  (B) 
Overexpression of Ctip2 in Q7 and Q111 cells rescues IPMK protein levels.  Bars 
represent means ± SEM normalized to β-actin (n=3).  *p<0.05 relative to Q111 empty 





Negative feedback regulation is a common feature of signaling pathways and is required 
to maintain the pathway at homeostatic levels.  Since Ctip2 overexpression did not alter 
IPMK levels in Q7 cells, we wondered whether feedback inhibition is also involved in 
the Ctip2/IPMK signaling pathway.  Ctip2 expression is upregulated by approximately 
40% in the striatum of Nestin-cre; IPMKfl/fl animals compared to IPMKfl/fl controls 
(Figure 3.8A).  This suggests that IPMK or other downstream components of this 
pathway, or other transcriptional targets of Ctip2 inhibit Ctip2 expression.  Therefore, it 
is possible that proteins involved in the negative feedback regulation of the pathway act 
directly by altering Ctip2 expression and/or activity.  When overexpressed in HEK293 
cells, Ctip2 co-immunoprecipitates with IPMK (Figure 3.8B).  These preliminary data 
suggest a potential role for IPMK as a negative feedback regulator of Ctip2.  
Furthermore, since Ctip2 is known to regulate several hundred proteins (66), IPMK might 
also indirectly be an important player in maintaining cellular homeostasis.  
 
Thus far we describe the transcriptional regulation of IPMK by Ctip2.  Furthermore, 
preliminary evidence suggests a role for IPMK in the negative feedback regulation of 













Figure 3.8.  Role of IPMK in the negative feedback regulation of Ctip2.    
(A) Ctip2 protein levels are elevated in adult Nestin-Cre; IPMKfl/fl striatum relative to 
IPMKfl/fl control mice.  Bars represent means ± SEM normalized to GAPDH (n=3).  
*p<0.05 relative to control.  (B) Co-immunoprecipitation assay of HEK293 cells 







3.3.3 Regulation of IPMK at the protein level 
 
Since the depletion of IPMK protein in Q111 cells is substantially greater than the loss of 
IPMK mRNA, we investigated whether HD is associated with alterations in IPMK 
protein stability.  We monitored the turnover of IPMK by examining its rate of depletion 
following inhibition of protein synthesis with cycloheximide (Figure 3.9).  In Q7 cells, 
cycloheximide treatment requires about 8 h to secure 45% depletion.  By contrast, 4 h 
after cycloheximide administration, IPMK protein levels in Q111 cells are reduced about 
80%.  The calculated half-life for IPMK turnover in Q7 cells is 8.9 h, which is reduced to 
2 h in Q111 cells.   
 
There are two main protein degradation pathways: the ubiquitin-proteasome system and 
the lysosomal degradation pathway (124).  We sought to determine whether these 
pathways contribute to altered IPMK protein stability and/or reduced IPMK expression in 
HD.  Impairing the proteasomal degradation pathway using MG132 does not alter IPMK 
protein levels in Q7 and Q111 cells (Figure 3.10A).  By contrast, inhibition of the 
lysosomal degradation pathway using bafilomycin rescues IPMK protein levels in Q111 
cells (Figure 3.10B).  Thus, IPMK depletion in Q111 cells is associated with decreased 
protein stability involving lysosomal degradation as well as diminished IPMK 









Figure 3.9.  IPMK protein stability is altered in a cellular model of HD    
IPMK protein levels in Q7 and Q111 cells following treatment with translational inhibitor 
cycloheximide (CHX).  Bars represent means ± SEM normalized to β-actin or GAPDH 
(n=4).  For Q7 cells, **p<0.01 and *p<0.05 relative to the Q7 0-h CHX treatment 











Figure 3.10.  Lysosomal protein degradation contributes to altered IPMK protein 
levels in HD  
(Figure on following page) 
 
(A) Treatment of Q7 and Q111 cells with proteasomal inhibitor MG132 did not alter 
IPMK protein expression.  Bars represent means ± SEM normalized to β-actin (n=3).  
*p<0.05 and **p<0.01 relative to Q7 control.  (B) Bafilomycin (Baf), an inhibitor of 
lysosomal degradation, restores IPMK protein levels in the Q111 cells without altering 
IPMK protein levels in the Q7 cells.  Bars represent means ± SEM normalized to β-actin 






Figure 3.10.  Lysosomal protein degradation contributes to altered IPMK protein 
levels in HD  




One potential mechanism for depleting IPMK might involve mHtt binding IPMK and 
increasing turnover.  We examined this possibility by monitoring binding between the 
two proteins in a HEK293 overexpression model (Figure 3.11A).  IPMK binds robustly 
to the N-terminal fragment of mHtt (N171-82Q) but not to wild type Htt (N171-18Q).  
Mapping experiments indicate that binding to mHtt is determined predominantly by the 
N-terminal portion of IPMK, as IPMK fragments 1-124 and 1-209 bind robustly to mHtt, 
while fragments 125-416 and 210-416 bind very little (Figure 3.11B).  These results are 




















Figure 3.11.  IPMK binds selectively to mHtt  
(Figure on following page) 
 
(A) Co-immunoprecipitation assay of HEK293 cells transfected with plasmids expressing 
myc-tagged human IPMK and the N-terminal fragment of either wild type Htt (Htt-flag) 
or mHtt (mHtt-flag).  IPMK binds selectively to the N-terminal fragment of mHtt and not 
wild type Htt.  (B) N-terminal fragments (1-124 and 1-209) and C-terminal fragments 
(125-416 and 210-416) of human IPMK were overexpressed with the N-terminal 
fragment of mHtt (mHtt-flag) in HEK293 cells.  Co-immunoprecipitation assays indicate 
that the N-terminal fragments of IPMK bind mHtt.  (C) Diagram of IPMK demonstrating 
the positions of the fragments and their interactions with binding partners of IPMK.  The 
key domains for inositol binding (IP), ATP binding (ATP), and catalytic activity (Ser-













Figure 3.11.  IPMK binds selectively to mHtt 






3.3.4 Role of IPMK in neuronal dysfunction 
 
IPMK has both pro-survival and pro-apoptotic effects due to the myriad of downstream 
signaling targets, which differ based on the cellular context.  We wondered whether the 
depletion of IPMK in HD contributes to the pathophysiology and behavioral phenotypes 
in HD.  If this were the case, then restoring the depleted IPMK should be beneficial.  We 
assessed mitochondrial metabolic activity of cells by the MTT assay (Figure 3.12A).  
Metabolic activity of Q111 cells is only half that of Q7 cells (183).  Overexpressing 
IPMK alleviates this abnormality (Figure 3.12A).   
 
IPMK possesses inositol phosphate kinase and PI3-kinase activities, and also displays 
various non-catalytic actions (7, 10, 11, 51, 184).  To ascertain which of these activities 
mediates the beneficial effects of IPMK, we overexpressed IPMK K129A-S235A 
(IPMK-KASA), which is devoid of both inositol phosphate kinase and PI3-kinase 
activities.  We also overexpressed the Arabidobsis thaliana ortholog, atIPK2, which 
possesses inositol phosphate kinase but not PI3-kinase activity and has been shown to 
restore inositol phosphate production in IPMK null MEFs (7).  Neither IPMK-KASA nor 
atIPK2 rescue the depressed metabolic activity of Q111 cells (Figure 3.12B).  The lack 
of activity of IPMK-KASA indicates that catalytic activity of IPMK is required for 
rescue.  The inactivity of atIPK2 suggests that PI3-kinase activity of IPMK is 







Figure 3.12.  The lipid kinase activity of IPMK rescues the mitochondrial metabolic 
activity deficit in a cellular model of HD 
(Figure on following page) 
 
 (A) Q7 and Q111 cells were transfected with 1 or 2 µg mouse IPMK plasmid.  IPMK 
rescues the mitochondrial metabolic activity deficit in Q111 cells as measured by the 
MTT assay.  Bars represent means ± SEM (n=6 for Q7 and Q111 empty vector controls 
and n=4 for IPMK overexpression groups).  *p<0.05 and ****p<0.0001 relative to the 
Q7 empty vector control.  **p<0.01 relative to the Q111 empty vector control.  (B) The 
IPMK activity required to rescue the metabolic activity deficit in Q111 cells was 
identified.  Q7 and Q111 cells were transfected with either wild type IPMK, which 
displays non-catalytic and catalytic activities, the kinase-dead mutant of IPMK (IPMK-
KASA), which lacks both PI3-kinase and soluble inositol phosphate kinase activities, or 
atIPK2β, which displays only soluble kinase activity.  Neither IPMK-KASA nor atIPK2β 
rescued the metabolic activity deficit as measured by the MTT assay.  Bars represent 
means ± SEM (n=4).  *p<0.05 and **p<0.01 relative to the Q7 empty vector control 












Figure 3.12.  The lipid kinase activity of IPMK rescues the mitochondrial metabolic 
activity deficit in a cellular model of HD  









The PI3-kinase activity of IPMK generates PIP3, which is indirectly visualized using a 
GFP-tagged Akt pleckstrin homology domain construct (Akt-PH-GFP).  In general, GFP 
fluorescence localizes to the membrane in the presence of PIP3 and remains diffuse in the 
cytoplasm in the absence of PIP3.  In Q7 cells, Akt-PH-GFP is localized to the cell 
membrane, indicating the presence of PIP3 (Figure 3.13A).  In Q111 cells, Akt-PH-GFP 
expression is diffuse throughout the cytoplasm, but localizes to the cell membrane upon 
over-expression of IPMK, consistent with increased PIP3 production (Figure 3.13B).   
 
PIP3 physiologically activates Akt protein kinase.  Akt signaling deficits have previously 
been described in HD striatum and lymphoblasts (185).  We observe a 70% - 80% 
depletion of phospho-Akt levels in Q111 cells at the T308 and S473 sites (Figure 3.14A 
and Figure 3.14B).  The loss of phospho-Akt at both sites is reversed by overexpressing 
IPMK in Q111 cells (Figure 3.15A and Figure 3.15B).   
 
The loss of IPMK is pathogenic as assessed by mitochondrial metabolic activity in a 
cellular model of HD.  Restoring IPMK rescues the metabolic activity deficit in a lipid 
kinase activity-dependent manner.  This is consistent with the significant improvement in 





Figure 3.13. IPMK rescues Akt-PH-GFP localization in a cellular model of HD   
(A) Q7 cells were transfected with Akt-PH-GFP and either a control vector or IPMK-
mCherry.  Akt-PH-GFP is localized to the cell membrane with or without IPMK-
mCherry.  Localization to the cell membrane appears to increase in the presence of 
IPMK-mCherry.  (B) Q111 cells were transfected with Akt-PH-GFP and either a control 
vector or IPMK-mCherry.  In the presence of IPMK-mCherry, Akt-PH-GFP localizes to 







Figure 3.14. Akt signaling is altered in a cellular model of HD   
(A) Akt phosphorylation at the T308 site [p-Akt (T308)] is decreased in Q111 cells. Bars 
represent means ± SEM normalized to total Akt (n=3).  **p<0.01 relative to the Q7 
control.  (B) Akt phosphorylation at the S473 site [p-Akt (S473)] is also decreased in 
Q111 cells. Bars represent means ± SEM normalized to total Akt (n=3).  **p<0.01 








Figure 3.15. Akt signaling deficit in a cellular model of HD is rescued by IPMK   
(A) IPMK overexpression rescues the loss of p-Akt (T308).  Bars represent means ± 
SEM normalized to total Akt (n=4).  *p<0.05 relative to the Q111 empty vector control 
sample.  (B) IPMK overexpression rescues the loss of p-Akt (S473).  Bars represent 
means ± SEM normalized to total Akt (n=4).  *p<0.05 relative to the Q111 empty vector 
control sample.   
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3.3.5 Effect of IPMK down-regulation on HD phenotype in vivo  
 
IPMK is protective in the cellular model of HD.  Thus, we hypothesized that either down-
regulating or over-expressing IPMK in an animal model of HD would worsen or reverse 
the behavioral phenotype, respectively.  Since IPMK gene knockout is embryonic lethal 
in mice (42), the R6/2 mice (also referred to as HD mice) were crossed with IPMK Het 
mice to study the effect of IPMK down-regulation on HD behavioral phenotype.  Despite 
the smaller litter size, all four possible genotypes from the R6/2 and IPMK Het breeding 
pairs (wild type, HD, IPMK Het, and HD;IPMK Het) were observed in equal Mendelian 
ratios (Table 3.4).  Male and female F1 mice were born in equal numbers.  The R6/2 
transgenic mouse model of HD is one of the most severe models of the disease.  These 
animals display early and rapid deficits in locomotor activity, motor coordination, and 
general habitus, which become more pronounced as the disease progresses.  Onset of 
motor symptoms occurs at approximately five to eight weeks of age depending on the 
behavioral test selected.   
 
HD and HD;IPMK Het animals demonstrate a similar decline in body weight and 
survival (Figure 3.16A and Figure 3.16B).  Furthermore, the loss of one allele of IPMK 
does not further impair rotarod performance (Figure 3.17) or open field activity (data not 
shown).  Since IPMK Het mice do not exhibit an overt phenotype but IPMK knockout 
animals are embryonic lethal, IPMK is likely happlosufficient.  Furthermore, the severity 






Table 3.4.  Genotype ratio of R6/2 and IPMK heterozygous crossing 
 
 WT HD IPMK Het HD;IPMK Het total 
Male 8 6 7 5 26 
Female 10 7 4 7 28 


















Figure 3.16.  Weight and survival of F1 generation from R6/2 and IPMK Het pair 
(A) R6/2 and R6/2;IPMK Het animals show a similar and gradual decrease in body 
weight over time.  IPMK Het mice display a normal weight gain comparable to WT 
animals (n=8 for wild type, n=7 for IPMK Het, n=6 for R6/2, n=5 for R6/2;IPMK Het).  
(B) The Kaplan-Meier curve indicates that the loss of one allele of IPMK in R6/2 animals 
does not significantly alter survival compared to R6/2 mice. Both male and female 
animals were included in similar ratios for the survival curve (n=18 for wild type, n=11 





Figure 3.17.  Loss of allele of IPMK does not alter R6/2 rotarod performance 
R6/2 and R6/2;IPMK Het animals display similar deficits on rotarod testing.  IPMK Het 
rotarod performance is comparable to wild type animal (n=7 for wild type, n=7 for IPMK 














3.3.6 Effect of IPMK delivery on HD phenotype in vivo  
 
We next investigated the effects of IPMK overexpression on striatal pathology and 
behavioral phenotype of R6/2 mice.  Direct administration of IPMK-expressing AAV2 in 
the striatum of R6/2 mice covers almost half of the striatal area (Figure 3.18A) at two 
weeks post-injection.  We confirmed robust expression of IPMK in the striatum 10 weeks 
post-injection (Figure 3.18B).  Interestingly, the expression of the unknown 49-kDa band 
is also elevated in tissues obtained from animals receiving the IPMK virus.  The 
intrastriatal injections were performed at 3 weeks of age.  Behavioral phenotypes were 
assessed at 6, 8, and 10 weeks of age.  Striatal pathology was studied at 10 weeks (Figure 
3.18C).       
 
Although no effects were observed on weight and survival (Figure 3.19A and Figure 
3.19B), viral overexpression of IPMK in the striatum of R6/2 mice reduced the number of 
EM48-positive mHtt aggregates by approximately 75% at 10 weeks of age (Figure 3.20A 
and Figure 3.20B).  Furthermore, the size of these aggregates also decreased by about 
30% (Figures 3.20C).  No changes in aggregate number or size were observed in the 
cortex, which did not receive IPMK (Figure 3.20D).   
 
HD striatal pathology also includes a decline in the size of MSN (186).  Thus, Nissl 
staining was used to assess neuronal size.  IPMK overexpression in wild type animals did 
not affect MSN size (Figure 3.21A) whereas IPMK delivery in R6/2 mice appears to 









Figure 3.18.  AAV2-mediated delivery of IPMK in striatum of R6/2 animals 
(A) Coronal section of mouse brain demonstrating intrastriatal virus expression two 
weeks post-injection.  (B) Striatal tissue obtained from R6/2 mice 10 weeks post-
injection with either GFP control AAV2 (denoted C) or IPMK-expressing AAV2 
(denoted I) confirm increased IPMK expression in wild type and R6/2 animals receiving 
IPMK-expressing AAV2.  (C) Intrastriatal injections were performed at 3 weeks followed 









Figure 3.19.  IPMK overexpression does not affect body weight and survival of R6/2 
animals 
(A) R6/2 mice injected with either control or IPMK virus show a similar and gradual 
decrease in weight over time.  IPMK overexpression did not affect wild type (WT) mice.  
(n=10 for wild type with control virus, n=9 for wild type with IPMK virus, n=17 for R6/2 
with control virus, and n=13 for R6/2 with IPMK virus).  (B) The Kaplan-Meier curve 
indicates that striatal overexpression of IPMK did not alter survival in wild type or R6/2 
mice (n=10 for wild type with control virus, n=11 for wild type with IPMK virus, n=11 






Figure 3.20.  Effect of IPMK on EM48-positive aggregates 
(Figure on following page) 
 
(A) EM48-positive mHtt aggregates are present in R6/2 striatum and absent in wild type 
striatum.  Virus-mediated over-expression of IPMK reduces the number and the size of 
mHtt aggregates. Scale bar represents 50 µm.  (B) Quantitation of number of mHtt 
aggregates per 40x field of view measuring 0.1 mm2.  Bars represent mean number of 
aggregates ± SEM (n=3 animals).  **p<0.01 relative to the number of R6/2 control 
aggregates.  (C) Quantitation of size of mHtt aggregates based on cross-sectional area of 
aggregates.  Bars represent mean size of aggregates ± SEM (n=3 animals).  *p<0.05 
relative to the size of aggregates in R6/2 control sections.  (D) EM48-positive mHtt 
aggregates are also evident in R6/2 cortex and used as a negative control.  No changes in 


















Figure 3.20.   Effect of 
IPMK on EM48-positive 
aggregates 







Figure 3.21.  IPMK delivery improves medium spiny neuron size 
(A) Overexpression of IPMK in wild type animals does not alter the size of MSNs as 
visualized by Nissl staining.  Scale bar represents 20 µm. (n=3 animals per group).  (B) 
MSNs in R6/2 animals appear smaller in size compared to wild type MSNs as detected 
by Nissl staining.  IPMK overexpression in R6/2 animals appears to rescue MSN size.  
Scale bar represents 50 µm (n=3 animals per group).  
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Changes in reactive astrocytes measured by GFAP immunoreactivity was also 
investigated.  Little reactive astrocytosis is present in wild type striatum (Figure 3.22) and 
most was associated with the injection tract.  There is evidence of mild astrogliosis in 
R6/2 striatum as previously reported (187).  However, IPMK delivery did not affect 
astrogliosis (Figure 3.22).  Due to AAV2-mediated delivery, only neurons expressed 
IPMK.  Thus, IPMK might not influence astrocyte function in these in vivo studies.    
 
The pathological changes described correspond with the delay in motor deficits observed 
in R6/2 animals.  Repletion of IPMK restores central locomotor activity of the R6/2 mice 
to levels that are not significantly lower than those of wild type mice at 6 weeks (Figure 
3.23).  However, IPMK overexpression does not significantly improve rotarod 
performance (Figure 3.24A) likely due to the earlier onset of this particular deficit.  In a 
balance beam model, the time to cross is increased 8-fold in R6/2 mice compared to wild 
type animals (Figure 3.24B).  This time is reduced by half in IPMK-replenished mice.  
We also evaluated a composite phenotype (180) of HD abnormalities, which consist of 
hindlimb clasping, gait abnormalities, kyphosis and ledge walking (Figure 3.25A).  The 
composite phenotype score is reduced almost by half with IPMK repletion.  This is 
consistent with improvement in gait, specifically stride length, in R6/2 mice receiving the 
IPMK-expressing virus (Figure 3.25B and Figure 3.25C).  Furthermore, there is reduced 
forepaw-hindpaw print overlap in the R6/2 animals, which appears to improve with 
IPMK delivery (Figure 3.25C).  We did not observe significant differences in balance 
beam and composite score in R6/2 animals relative to wild type mice prior to 10 weeks of 









Figure 3.22.  IPMK does not alter reactive astrocytosis 
GFAP staining confirms the absence of reactive astrocytes in wild type tissue with or 
without IPMK over-expression.  Mild astrocytosis is observed in R6/2 animals and is not 
affected by neuron-specifc AAV2-mediated IPMK delivery.  Scale bar represents 50 µm 
















Figure 3.23.  Virus-mediated expression of IPMK delays open field deficits  
IPMK overexpression delays impairment of central locomotor activity.  Bars represent 
means ± SEM beam breaks (n=9-12 animals per group).  *p<0.05 and **p<0.01 relative 















Figure 3.24.  Virus-mediated delivery of IPMK improves motor coordination 
impaired in late disease stage   
(A) IPMK overexpression does not affect rotarod performance at 6, 8, and 10 weeks of 
age.  Bars represent means ± SEM time to fall in seconds (n=7-11 animals per group).  
*p<0.05, **p<0.01 and ***p<0.001 relative to wild type mice injected with either control 
or IPMK virus.  (B) IPMK restores motor coordination and balance assessed by balance 
beam performance.  Bars represent means ± SEM total time to cross beam (n=7-10 
animals per group).  **p<0.01 and ****p<0.0001 relative to either wild type or R6/2 






Figure 3.25.  Virus-mediated delivery of IPMK improves gait and general 
phenotype 
(Figure on following page) 
 
(A) General phenotype based on clasping, kyphosis, gait, and ledge walking are 
presented as a composite score, which is improved by IPMK overexpression.  Bars 
represent means ± SEM (n=9-10 animals per group).  *p<0.05 relative to R6/2 mice 
receiving control virus.  (B) IPMK overexpression improves R6/2 animal gait, 
specifically stride length at 10 weeks of age.  Bars represent means ± SEM stride length 
in centimeters (cm) (n=6-10 animals per group).  *p<0.05, **p<0.01 and ****p<0.0001 
relative to wild type mice or R6/2 mice injected with control virus as indicated.  (C) 
Representative footprint test results with forepaws and hindpaws indicated in red and 










Figure 3.25.  Virus-mediated delivery of IPMK improves gait and general 
phenotype 








In the present study we report a dramatic depletion of IPMK in post-mortem HD striatal 
tissues, as well as in Q111 HD cells and the R6/2 and zQ175 murine models of HD.  The 
depletion of IPMK occurs at both transcriptional and protein stability levels and 
corresponds with decreased Akt signaling.  IPMK depletion appears to mediate, at least 
in part, the pathology and motor deficits in HD.  Viral expression of IPMK in the striatum 
of R6/2 mice, the brain region primarily affected in clinical HD, delays locomotor 
deficits of the animals and reduces the number and size of aggregates.       
 
The striatal-enriched transcription factor Ctip2 appears to determine IPMK transcription.  
Its overexpression reverses the IPMK depletion in Q111 cells.  Ctip2 protein itself is also 
selectively expressed in striatal medium spiny neurons (151), the cell type uniquely lost 
in HD (182).  The depletion of Ctip2 in the striatum, cortex and hippocampus of R6/2 
mice is consistent with the altered expression pattern of IPMK in these mice.  
Interestingly, Ctip2 overexpression in Q7 cells does not change IPMK protein levels 
suggesting a potential negative feedback effect of IPMK or other targets on Ctip2 
expression and/or transcriptional activity.  This is further supported by the increased 
expression of Ctip2 in conditional IPMK knockout animals.   
 
Altered IPMK protein stability and lysosomal degradation also contribute to the loss of 
IPMK protein in the cellular model of HD.  Although macroautophagy and the ubiquitin 
proteasome system are both impaired in HD, chaperone-mediated autophagy is 
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constitutively up-regulated in early stages of the disease, thereby increasing the turnover 
of both wild type Htt and mHtt fragments (128).  The selective interaction of IPMK with 
the N-terminal fragment of mHtt might explain the loss of IPMK through lysosomal 
degradation in Q111 cells but not Q7 cells.       
 
We provide several lines of evidence that the depletion of IPMK is pathogenic in HD.  
Overexpressing IPMK restores to normal the depressed mitochondrial metabolic activity 
of Q111 cells, an action that appears to be determined by the PI3-kinase activity of 
IPMK.  IPMK and the p110 PI3-kinase act coordinately in generating PIP3 (7), a classic 
stimulant of Akt (188).  Phospho-Akt depletion in Q111 cells is rescued by 
overexpressing IPMK.  Overexpression of constitutively active Akt is sufficient to rescue 
pathologic phenotypes, such as the formation of nuclear inclusions, in primary rat brain 
cultures expressing mHtt (101).  Akt also regulates inclusions indirectly by 
phosphorylating other proteins such as the ADP-ribosylation factor-interacting protein 
arfaptin2, which rescues mHtt-induced proteasomal impairment and decreases neuronal 
intranuclear inclusions (189).  Compensatory mechanisms have been shown to target Akt 
and increase its activation during early stages of HD.  Decreased levels of PH domain 
leucine-rich repeat protein phosphatase 1 (PHLPP1), a phosphatase that targets the S473 
site of Akt, contribute to enhancement of Akt phosphorylation at early stages of HD 
(190). 
 
Akt also rescues additional cellular deficits caused by mHtt.  mHtt is phosphorylated by 
Akt at the S421 site, which restores fast axonal transport by altering the mHtt interaction 
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with dynactin (191).  Conversely, excitotoxic stimulation of NMDA receptors reduces 
mHtt S421 phosphorylation (192).  mHtt increases the mitochondrial susceptibility to 
Ca2+-induced mitochondrial depolarization (193).  In healthy cells, these depolarized 
mitochondria are targeted for autophagy by parkin, in a process that requires hexokinase 
2 (HK2) (194).  Akt, which is known to promote cell survival, phosphorylates HK2 at the 
T473 residue thereby increasing HK2 association with mitochondria (195).  Impaired Akt 
signaling in HD could thus be affecting mitophagy thereby contributing to mitochondrial 
dysfunction.   
 
As the R6/2 animals used in this study express the N-terminal fragment of mHtt, rather 
than full-length mHtt, the observed effects of IPMK likely do not require direct 
phosphorylation of mHtt by Akt.  Thus, through the multiple downstream effects of Akt, 
including arfaptin2, IPMK deficits may account for the notably pleiotropic manifestations 
of HD.  The lipid kinase activity of IPMK may have additional functions in the context of 
HD.  IPMK is required for mRNA export of specific transcripts such as the recombinase 
Rad51, which is associated with double-stranded DNA break repair (56).  DNA repair 
responses to genotoxic stress are impaired in HD (196, 197).   
 
Several signaling pathways implicated in HD converge on Akt.  The BDNF pathway is 
altered in HD due to decreased transcription and release of BDNF at the corticostriatal 
synapses (141, 198), as well as impaired TrkB receptor signaling (143).  Augmenting this 
pathway may be beneficial, as TrkB agonists extend survival in murine models of HD 
(199).  Similarly, synaptic, but not extrasynaptic, NMDA receptors enhance Akt 
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phosphorylation and neuroprotection (200).  More recently, the CB1 cannabinoid 
receptor, which is highly expressed in MSNs, was found to exert neuroprotective effects 
through the activation of the PI3K/Akt pathway.  Viral-mediated over-expression of CB1 
rescued pathological deficits in R6/2 mice (201). 
 
Intrastriatal delivery of IPMK in R6/2 mice similarly improved neuropathological and 
motor deficits in the R6/2 model of HD.  IPMK overexpression had the greatest effects 
on balance beam performance and gait.  The motor deficits assessed using these tests 
appear during later symptomatic stages (after 8.5 weeks of age) in R6/2 animals (169).  
IPMK overexpression resulted in moderate to no effects on open field and rotarod testing, 
respectively, likely because the corresponding motor deficits occur at five weeks of age.  
Thus, earlier delivery of IPMK may have greater effects on the behavioral phenotype of 
these R6/2 animals.  In addition to motor deficits, early clinical manifestations of HD 
include cognitive symptoms (72).  IPMK regulates the induction of immediate early 
genes, required for learning, memory and behavior, as mice deleted for IPMK display 
aberrant spatial memory (11).   
 
Altered histone modifications contribute to transcriptional dysregulation in HD.  H3K4 
trimethylation (H3K4me3) patterns in HD are rescued when expression of Jarid1c, an 
H3K4me3 demethylase, is reduced (202).  Furthermore, HDAC4 knock-down restores 
deficient BDNF transcription in R6/2 mice (203), and the HDAC inhibitor, 
suberoylanilide hydroxamic acid, rescues motor deficits in R6/2 mice (174).  HDAC 
complex formation requires IP4 (37).  Thus, the soluble inositol phosphate product of 
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IPMK enhances histone deacetylase activity.  However, it is unclear how the lipid kinase 
and inositol phosphate kinase activities of IPMK are differentially regulated.  In vitro 
competition assays indicate that the IPMK substrate PIP2 competes successfully with IP3 
and IP4 (51), which might be expected to favor the PI3-kinase activity of IPMK.   
 
The inositol phosphate kinase activity of IPMK also generates IP5, which inhibits the PH 
domain of Akt and subsequently impairs Akt signaling (24-27).  Therefore, the inositol 
phosphate kinase activity of IPMK directly opposes the effects of its lipid kinase activity.  
Although the catalytic sites of IPMK may have higher affinity for PIP2 compared to the 
inositol phosphates (51), it is necessary to study the molecular mechanisms that regulate 
the switch in the catalytic activities of IPMK.  
 
Additional clinical features of HD include peripheral organ dysfunction such as weight 
loss, skeletal muscle wasting, as well as metabolic and endocrine alterations (75).  IPMK 
influences metabolism by inhibiting AMPK activation (9).  AMPK promotes catabolic 
pathways while inhibiting various anabolic pathways such as cholesterol and triglyceride 
synthesis (60).  Interestingly, a pathologic increase in AMPK phosphorylation has been 
demonstrated in HD patients and in the R6/2 model (204).  IPMK delivery in R6/2 
animals did not improve body weight and survival, probably because IPMK was 
expressed only in the striatum.  Conceivably, widespread expression of IPMK in HD 




The circadian rhythm is also altered in HD (76).  Microarray analysis of SRF-treated wild 
type and IPMK null MEFs indicate that period circadian clock 1 (Per1) is down-regulated 
in the absence of IPMK (62).  Per1 acts in concert with several other core clock proteins 
to regulate circadian rhythm.  Interestingly, AMPK is thought to transmit energy-
dependent signals to the molecular clock by destabilizing Per proteins and cryptochrome 
(Cry) proteins (205).  Furthermore, impaired function of other clock genes including 
brain and muscle Arnt-like protein 1 (Bmal1), circadian locomotor output cycles kaput 
(Clock), and neuronal PAS domain protein 2 (Npas2), have been implicated in 
neurodegeneration (206).  The expression of the clock genes Per1, Per2, Cry2 and Bmal1 
were not altered in the suprachiasmatic nucleus of conditional IPMK knockout animals 
(data not shown).  Since SRF is an immediate early transcription factor responding to 
peripheral stimuli (207), further studies include investigating the effects of IPMK on 
clock gene expression in peripheral organs such as the liver.  IPMK may be influencing 
aspects of circadian rhythm dysfunction in HD through SRF.    
 
Several proteins, specifically mTOR, Dvl3, CBP, AMPK, and p53 have been shown to 
bind to specific exons of IPMK.  The interaction of mHtt with the N-terminal fragment of 
IPMK might interfere with non-catalytic functions of IPMK that require this binding site, 
specifically mTOR, Dvl3, CBP, and SRF.  The effect of mHtt on these pathways remains 
to be investigated.  
 
The small G-protein Rhes sumoylates mHtt resulting in cytotoxicity (159), which is 
further enhanced through the interaction of Rhes and mHtt with acyl-CoA binding 
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domain containing 3 (ACBD3) (208).  An in vivo screen for SUMO1 substrates 
demonstrated that Ctip2 is sumoylated (156).  Perhaps Rhes also modulates the Ctip2-
IPMK-Akt signaling pathway through the regulation of Ctip2 or IPMK. 
 
Our findings suggest that the IPMK depletion in HD is pathogenic by dint of diminished 
PI3-kinase activity with less PIP3 available to activate Akt.  Approaches targeting the 





















Huntington’s disease (HD) is a progressive neurodegenerative disorder mainly affecting 
the striatum.  The striatal-enriched protein Ctip2 is depleted in HD and has been 
identified as a putative transcription factor for IPMK, a multi-functional enzyme with a 
soluble inositol phosphate kinase activity, a lipid kinase activity, and several non-
catalytic activities including its role as a transcriptional co-activator.   
 
The present study implicates the impairment of the Ctip2-IPMK-Akt signaling pathway 
in the pathophysiology of HD (Figure 3.26).  IPMK is depleted in post-mortem HD 
striatal tissues and various cellular and animal models of the disease.  The reduced levels 
of IPMK protein and mRNA result from mHtt-induced loss of expression and function of 
Ctip2, as well as decreased IPMK protein stability. Over-expression of IPMK rescues the 
mitochondrial metabolic activity deficit in a cell model of HD. This rescue requires the 
lipid kinase activity of IPMK, thereby involving the Akt signaling pathway. Consistent 
with the cellular data, over-expression of IPMK in the striatum improves the striatal 
pathology and psychomotor performance of a transgenic mouse model of HD.   
 
Although our studies mainly focused on the role of IPMK in modulating Akt signaling in 
the striatum, this pleiotropic enzyme may also be involved in other aspects of HD 
pathogenesis, including mitochondrial deficits, impaired axonal transport, and peripheral 
organ dysfunction.  Additional studies focusing on the other systemic effects of IPMK, as 
well as the mechanisms regulating IPMK activity, are required to better understand the 
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role of this multi-functional protein in the complex network of impaired pathways and 
cellular processes resulting in HD.  The Ctip2-IPMK-Akt signaling pathway provides a 
novel therapeutic target and approach to enhancing Akt signaling in HD and potentially 
























Figure 3.26.  Summary of Ctip2-IPMK-Akt signaling pathway in HD 
In normal striatal cells, Ctip2 induces IPMK.  IPMK displays several functions including 
the lipid kinase activity, which enhances Akt signaling.  In HD, Ctip2 transcriptional 
activity and expression is inhibited by mHtt resulting in decreased IPMK transcription.  
Decreased IPMK protein stability, likely caused by the selective interaction with mHtt, 
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